

Updated 6.18.26



CURRICULUM VITAE

DAVID JOEL MARON, M.D.

PERSONAL INFORMATION:

Title: C.F. Rehnborg Professor of Medicine

Office Address: 3180 Porter Drive
A103
Palo Alto, CA 94304

Phone: 650-275-4698 (office); 650-468-9979 (mobile)

E-mail: david.maron@stanford.edu

EDUCATION:

1972-1976 Stanford University B.A. (with Distinction), Human Biology

1977-1981 University of Southern California, M.D.

POSTGRADUATE TRAINING:

1981-1982 Intern, Internal Medicine
UCLA Medical Center

1982-1984 Resident, Internal Medicine
UCLA Medical Center

1984-1986 Postdoctoral Research Fellow in Cardiovascular Disease
Epidemiology and Prevention, Stanford Center for Research in
Disease Prevention, Stanford University

1984-1986 Robert Wood Johnson Clinical Scholar, Stanford University

1989-1991 Cardiology Fellow, Stanford University

LICENSURE:

State of California 1982 (G48267)
State of Tennessee 1993 (MD024919; inactive)

CERTIFICATION:

1981 National Board of Medical Examiners

1984 American Board of Internal Medicine

1991 American Board of Internal Medicine—Cardiovascular Disease

2001	American Board of Internal Medicine—Cardiovascular Disease (Recertification)
2005	American Board of Clinical Lipidology
2011	American Board of Internal Medicine—Cardiovascular Disease (Recertification)
2017	American Board of Clinical Lipidology (Recertification)
2021	American Board of Internal Medicine—Cardiovascular Disease (Recertification)

PROFESSIONAL APPOINTMENTS:

1984-1989	Clinical Instructor, Department of Medicine Stanford University School of Medicine
1986-1989	Physician Specialist, Department of Medicine Stanford University School of Medicine
1992-1993	Clinical Instructor, Department of Medicine UCLA School of Medicine
1993-2002	Assistant Professor of Medicine, Division of Cardiology Vanderbilt University School of Medicine
2002-2010	Associate Professor of Medicine, Division of Cardiology Vanderbilt University School of Medicine
2007-2010	Associate Professor of Emergency Medicine Vanderbilt University School of Medicine
2010-2013	Professor of Medicine, Division of Cardiology Vanderbilt University School of Medicine
2010-2013	Professor of Emergency Medicine Vanderbilt University School of Medicine
Jan 2014- Oct 2020	Clinical Professor of Medicine, Division of Cardiovascular Medicine Stanford University School of Medicine (Reappointed in 2019)
Oct 2020-present	Professor of Medicine (University Medical Line), Stanford Prevention Research Center and Division of Cardiovascular Medicine Stanford University School of Medicine

HOSPITAL STAFF APPOINTMENTS:

1986-1989	Director, Preventive Medicine Clinic
-----------	--------------------------------------

	Stanford University
1988-1989	Director, Preventive Cardiology Clinic Stanford University
1991-1993	Saint John's Hospital Santa Monica, CA
1991-1993	Santa Monica Hospital Santa Monica, CA
1992-1993	Medical Director, Cardiac Rehabilitation Program, Saint John's Hospital Santa Monica, CA
1993-2006	Nashville VA Hospital
1993-2013	Vanderbilt University Hospital
2014-present	Stanford University Hospital

OTHER EMPLOYMENT:

1991-1993	Cardiologist, Pacific Heart Institute, Santa Monica, CA
-----------	---

HONORS AND AWARDS:

1980	Alpha Omega Alpha
1985	Fellow, American Heart Association Council on Epidemiology, 10- day Seminar on the Epidemiology and Prevention of Cardiovascular Diseases
1994	Fellow, American College of Cardiology
1999-2000	Fellow, Health Forum Cardiovascular Health Fellowship
1996-2002, 2005-2022	Best Doctors in America
2001	Fellow, American Heart Association
2003	NIH Annual Bibliography of Significant Advances in Dietary Supplement Research (<i>Arch Intern Med</i> 2003;163:1448-53.)
2007-2022	America's Top Cardiologists
2008	Adult ED Advocate Award, presented by the faculty of the Department of Emergency Medicine to the physician from another department who

represents the highest ideals of patient advocacy and professionalism when dealing with patients and physicians in the emergency department

- 2010 Five Star Award (An Excellence in Healthcare Award given to physicians who score within the 90th to 99th percentiles in Vanderbilt patient satisfaction surveys)
- 2013 Five Star Award
- 2015 VINSE High Impact Paper Award (*Int J Nanomedicine* 2012;7:799-813.)
- 2018 Fellow, American Society for Preventive Cardiology
- 2020 Imel-Demots Lectureship. Oregon Health Sciences University (Virtual). 6/25/20 The ISCHEMIA Trial: Implications for Practice
- 2020 C.F. Rehnborg Endowed Professorship
- 2020 NEJM Editorial Board selected the ISCHEMIA trial as one of the NEJM Notable Articles of 2020
- 2020 NEJM Journal Watch Cardiology selected ISCHEMIA and ISCHEMIA-CKD as their 2020 Top Stories
- 2020 AHA named the primary report of the ISCHEMIA trial as one of the top heart disease and stroke research advances of 2020
- 2021 Clinical Research Forum selected the ISCHEMIA trial to receive its top prize, the Herbert Pardes, MD Clinical Research Excellence Award
- 2023 2023 Hearst Health Prize for excellence in data science in healthcare awarded to the Stanford incidental coronary calcium research team for the manuscript “Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project)” published in *Circulation*.
- 2023 2023 James T. Willerson Award in Clinical Science for the manuscript “Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project)” published in *Circulation*.
- 2024 2023 Editor-in-Chief’s Top Picks for the manuscript “Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging with Cardiovascular Outcomes” published in the *Journal of the American College of Cardiology*.
- 2024 President-Elect, American Society for Preventive Cardiology

2024	Top Scholar by ScholarGPS (within the top 0.5% of all scholars worldwide)
2025	National Forum for Heart Disease & Stroke Prevention 2025 Chair Recognition Award
2025	America's Leading Doctors
2026	Top Doctors 2026
2026	The Simon Dack, MD Visting Professor and Memorial Lecture (Mount Sinai Fuster Heart Hospital)

SCHOLARLY PUBLICATIONS:

A. Peer-reviewed journal articles (original research):

1. Killen JD, Taylor CB, Telch MJ, Saylor KE, **Maron DJ**, Robinson TN. Self-induced vomiting and laxative and diuretic use among teenagers: Precursors of the binge-purge syndrome? *JAMA* 1986; 255:1447-1449.
2. **Maron DJ**, Telch MJ, Killen JD, Vranizan KM, Saylor KE, Robinson TN. Correlates of seat belt use by adolescents: Implications for health promotion. *Prev Med* 1986; 15:614-623.
3. Killen JD, Taylor CB, Telch MJ, Saylor KE, **Maron DJ**, Robinson TN. Evidence for an alcohol-stress link among normal weight adolescents reporting purging behavior. *Int J Eating Dis* 1987; 6:349-356.
4. **Maron DJ**, Fortmann SP. Nicotine yield and measures of cigarette smoke exposure in a large population: Are lower-yield cigarettes safer? *Am J Public Health* 1987; 77:546-549.
5. Robinson TN, Killen JD, Taylor CB, Telch MJ, Bryson SW, Saylor KE, **Maron DJ**, Maccoby N, Farquhar JW. Perspectives on adolescent substance use: A defined population study. *JAMA* 1987; 258:2072-2076.
6. Killen JD, Taylor CB, Telch MJ, Robinson TN, **Maron DJ**, Saylor KE. Depressive symptoms and substance use among adolescent binge eaters and purgers: A defined population study. *Am J Public Health* 1987; 77:1539-1541.
7. Killen JD, Robinson TN, Telch MJ, Saylor KE, **Maron DJ**, Rich T, Bryson S. The Stanford Adolescent Heart Health Program. *Health Educ Q* 1989; 16:263-283.
8. Rucker DW, **Maron DJ**, Shortliffe EH. Temporal representation of clinical algorithms using expert-system and database tools. *Computers in Biomedical Research* 1990; 23:222-239.
9. Reynolds KD, Killen JD, Bryson SW, **Maron DJ**, Taylor CB, Maccoby N, Farquhar JW. Psychosocial predictors of physical activity in adolescents. *Prev Med* 1990; 19:541-551.
10. **Maron DJ**, Fair JM, Haskell WL. Saturated fat intake and insulin resistance in men with coronary artery disease. *Circulation* 1991; 84:2020-2027.
11. Haskell WL, Alderman EL, Fair JM, **Maron DJ**, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: The Stanford coronary risk intervention project (SCRIP). *Circulation* 1994;89:975-90.

12. Barrett TW, Norton VC, Busam M, Boyd J, **Maron DJ**, Slovis CM. Self-reported cardiac risk factors in emergency department nurses and paramedics. *PreHospital and Disaster Med* 2000;15:14-17.
13. Levenhagen DK, Gresham J, Carlson M, **Maron DJ**, Borel MJ, Flakoll PJ. Post-exercise nutrient intake timing is critical to recovery of leg glucose and protein homeostasis in humans. *Am J Physiol Endocrinol Metab* 2001;280:982-93.
14. Levenhagen D K, Carr C, Carlson MG, **Maron DJ**, Borel MJ, Flakoll, PJ. Postexercise protein intake enhances whole-body and leg protein accretion in humans. *Med Sci Sports Exerc* 2002;34:828-37.
15. **Maron DJ**, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC, Zhao J. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. *Arch Intern Med* 2003;163:1448-53.
16. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, **Maron DJ**, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey: implications for treatment under the recent NCEP Writing Group recommendations. *Am J Cardiol* 2005;96:556-563.
17. Clark LT, Maki KC, Galant R, **Maron DJ**, Pearson TA, Davidson MH. Ethnic differences in achievement of cholesterol treatment goals: results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. *J Gen Intern Med* 2006;21:320-326.
18. Shaw LJ, Heller GV, Casperson P, Miranda-Peats R, Slomka P, Friedman J, Hayes SW, Schwartz R, Weintraub WS, **Maron DJ**, Dada M, King S, Teo K, Hartigan P, Boden WE, O'Rourke RA, Berman DS. Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424. *J Nucl Cardiol* 2006;13:685-98.
19. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, **Maron DJ**, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GBJ, Berman DS, Weintraub WS. Design and Rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial: Veterans Affairs Cooperative Studies Program no. 424. *Am Heart J* 2006; 151:1173-79.
20. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, **Maron DJ**, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GBJ, Berman DS, Gau G, Weintraub WS. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: Baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. *Am J Cardiol* 2007;99:208-12.
21. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, **Maron DJ**, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Eric Bates, Spertus JA, Berman DS, Mancini GBJ, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356:1503-1516.
22. Shaw LJ, Berman DS, **Maron DJ**, Mancini GBJ, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE, for the COURAGE Investigators. Optimal medical therapy with or without percutaneous

- coronary intervention to reduce ischemic burden: results from the COURAGE trial nuclear substudy. *Circulation* 2008;117:1283-1291.
23. Weintraub WS, Spertus JA, Kolm P, **Maron DJ**, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE, on behalf of the Department of Veterans Affairs Cooperative Studies Program No.424 (COURAGE Trial) Investigators and Study Coordinators. Effect of PCI on quality of life in patients with stable coronary disease. *N Engl J Med* 2008;359:677-87.
 24. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, **Maron DJ**, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG. Cost-Effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. *Circ Cardiovasc Qual Outcomes* 2008;1:12-20.
 25. **Maron DJ**, Forbes BL, Groves JR, Dietrich MS, Sells P, DiGenio AG. Health-risk appraisal with or without disease management for worksite cardiovascular risk reduction. *J Cardiovasc Nurs* 2008;23:513-18.
 26. Boden WE, O'Rourke RA, Teo KK, **Maron DJ**, Hartigan, PM; Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, G.B. John Mancini GBJ, Weintraub WS, on behalf of the COURAGE Trial Investigators. Impact of optimal medical therapy with or without PCI on long-term cardiovascular endpoints in patients with stable coronary artery disease (from the COURAGE trial). *Am J Cardiol* 2009;104:1-4.
 27. Mancini GBJ, Bates ER, **Maron DJ**, Hartigan P, Dada M, Gosselin G, William Kostuk W, Sedlis SP, Shaw LJ, Berman DS, Berger P, Spertus J, Mavromatis K, Knudtson M, O'Rourke RA, Weintraub WS, Teo K, Boden WE, on behalf of the COURAGE Trial Investigators and Coordinators. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. *Circ Cardiovasc Qual Outcomes* 2009;2:320-27.
 28. Mathe JL, Martin JB, Miller P, Ledeczi A, Weavind L, Nadas A, Miller A, **Maron DJ**, Sztipanovits J. A model-integrated guideline-driven clinical decision-support system. *IEEE Software* 2009;26(4):54-61.
 29. Teo KK, Sedlis SP, MD, Boden WE, O'Rourke RA, **Maron DJ**, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LS, Chaitman BR, Mancini GBJ, Weintraub WS. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. *J Am Coll Cardiol* 2009;54:1303-8.
 30. **Maron DJ**, Spertus JA, Mancini GBJ, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. *Am J Cardiol* 2009;104:1055-62.
 31. Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, **Maron DJ**, Spertus JA, Mancini GBJ, Teo KK, O'Rourke RA, Boden WE, Weintraub WS, for the COURAGE study investigators. Optimal medical therapy with or without percutaneous coronary intervention for stable coronary artery disease in patients with chronic kidney disease. *Am J Cardiol* 2009; 104:1647-53.

32. **Maron DJ**, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GBJ, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LS, Berman DS, Chaitman BR, Weintraub WS, Teo KK. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. *J Am Coll Cardiol* 2010;55:1348-58.
33. Chaitman BR, Hartigan PM, Booth DC, Teo KK, Mancini GBJ, Kostuk WJ, Spertus JA, **Maron DJ**, Dada M, O'Rourke RA, Weintraub WS, Berman DS, Shaw LJ, Boden WE. Do major cardiovascular outcomes in patients with stable ischemic heart disease in COURAGE differ by healthcare system? *Circ Cardiovasc Qual Outcomes* 2010;3:476-83.
34. Zhang Z, Kolm P, Boden WE, Hartigan PM, **Maron DJ**, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GBJ, Berman DS, Dada M, Teo KK, Weintraub WS. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. *Circ Cardiovasc Qual Outcomes* 2011;4:172-82.
35. **Maron DJ**, Boden WE, Spertus JA, Hartigan PM, Mancini GBJ, Sedlis SP, Kostuk WJ, Chaitman BR, Shaw LJ, Berman DS, Dada M, Teo KK, Weintraub WS, O'Rourke RA. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (clinical outcomes utilizing revascularization and aggressive drug evaluation) trial. *J Am Coll Cardiol* 2011;58:131-137.
36. Mancini GBJ, Hartigan PM, Sedlis SP, **Maron DJ**, Spertus J, Berman DS, Kostuk WJ, Bates ER, Shaw LJ, Weintraub WS, Teo KK, Dada M, Chaitman BR, O'Rourke RA, Boden WE. Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE trial. *Circ Cardiovasc Interv* 2011;4:545-552.
37. **Maron DJ**, Stone GW, Berman DS, Mancini GBJ, Scott TA, Byrne DW, Harrell FE, Shaw LJ, Hachamovitch R, Boden WE, Weintraub WS, Spertus JA. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a web-based survey of cardiologists. *Am Heart J* 2011;162:1034-1043.
38. Yu SS, Lau CM, Thomas SN, Jerome WG, **Maron DJ**, Dickerson JH, Hubbell JA, Giorgio TD. Macrophages exhibit size-dependent nonspecific uptake of PEGylated nanoparticles and respond to MMP-9-triggered modulation of nanoparticle size. *Int J Nanomedicine* 2012;7:799-813.
39. Gosselin G, Teo KK, Tanguay J-F, Gokhale R, Hartigan PM, **Maron DJ**, Mancini GBJ, Bates ER, Chaitman BR, Spertus JA, Kostuk WJ, Dada M, Sedlis SP, Berman DS, Shaw LJ, O'Rourke RA, Weintraub WS, Boden WE. Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post-hoc analysis of the COURAGE trial). *Am J Cardiol*. 2012;109:954-959.
40. Collins SP, Lindsell CJ, Yealy DM, **Maron DJ**, Naftilan AJ, McPherson JA, Storrow AB. A comparison of criterion standard methods to diagnose acute heart failure. *Congest Heart Fail*. 2012;18:262-271.
41. Henry-Okafor Q, Collins SP, Jenkins CA, Miller KF, **Maron DJ**, Naftilan AJ, Weintraub N, Fermann GJ, McPherson J, Menon S, Sawyer DB, Storrow AB. Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes. *Open Biomarkers J*. 2012;5:1-8.

42. Henry-Okafor Q, Collins S, MD, Jenkins C, Miller KF, **Maron DJ**, Naftilan AJ, Weintraub N, Fermann GJ, McPherson J, Menon S, Sawyer DB, Storrow AB. Relationship between uric acid and diagnostic and prognostic outcomes in acute heart failure syndrome. *Open Biomarkers J.* 2012;5:9-15.
43. Shaw LJ, Weintraub WS, **Maron DJ**, Hartigan PM, Hachamovitch R, Min JK, Dada M, MD, Mancini GBJ, Hayes SW, O'Rourke RA, Spertus JA, Kostuk W, Gosselin G, Chaitman BR, Knudtson M, Friedman J, Slomka P, Germano G, Bates ER, Teo KK, Boden WE, Berman DS. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. *Am Heart J.* 2012;164:243-250.
44. Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M, Roll S, Weintraub NL, Miller KF, **Maron DJ**, Naftilan AJ, McPherson JA, Sawyer DB, Christenson R, and Collins SP. Galectin 3 complements BNP in risk stratification in acute heart failure. *Biomarkers.* 2012;17:706-13.
45. Huang RL, Thomasee E, Park JY, Scott C, **Maron DJ**, Fredi JL. Helicopter scene STEMI protocol to facilitate long-distance transfer for primary PCI. *Crit Pathw Cardiol.* 2012 Dec;11(4):193-198.
46. Collins SP, Lindsell CJ, Jenkins CA, Harrell FE, Fermann GJ, Miller KF, Roll SK, Sperling MI, **Maron DJ**, Naftilan AJ, McPherson JA, Weintraub NL, Sawyer DB, Storrow AB. Risk Stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studies. *Am Heart J.* 2012;164:825-34.
47. Farkouh ME, Boden W, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, **Maron DJ**, Sethi SS, Domanski M, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. *J Am Coll Cardiol.* 2013;61:1607-15.
48. **Maron DJ**, Hartigan PM, Neff DR, Weintraub WS, Boden WE. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial). *Am J Cardiol.* 2013;111:1557-62.
49. Spertus JA, **Maron DJ**, Kolm P, Hartigan PM, Aslan M, Weintraub WS, Berman DS, O'Rourke RA, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Kostuk W, Frutkin AD, Dada M, Boden WE, Mancini GBJ. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. *Circ Cardiovasc Qual Outcomes.* 2013;6:409-18.
50. Acharjee S, Boden WE, Hartigan PM, Teo KK, **Maron DJ**, Sedlis SP, William Kostuk W, Spertus JA, Marcin Dada M, Bernard R. Chaitman BR, Mancini GBJ, Weintraub WS. Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE trial. *J Am Coll Cardiol.* 2013;62:1826-33.
51. Sedlis SP, Jurkovitz CT, Hartigan PM, Kolm P, Goldfarb DS, Lorin JD, Dada M, **Maron DJ**, Spertus JS, Mancini GBJ, Teo KK, Boden WE, Weintraub WS. Health status and quality of life in stable coronary artery disease patients with chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial). *Am J Cardiol* 2013;112:1703-8.
52. Mancini GB, Hartigan PM, Bates ER, Chaitman BR, Sedlis SP, **Maron DJ**, Kostuk WJ, Spertus JA, Teo KK, Dada M, Knudtson M, Berman DS, Booth DC, Boden WE, Weintraub WS. Prognostic importance of coronary anatomy and left

- ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial. *Am Heart J* 2013;166:481-7.
53. Mancini GBJ, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, **Maron DJ**, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE. Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. *JACC Cardiovasc Interv* 2014;7:195-201.
 54. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Doran B, Guo Y, Xu J, Weintraub H, Mora S, **Maron DJ**, Bangalore S. *Circulation*. 2014;130:546-53.
 55. VanHouten JP, Starmer JM, Lorenzi NM, **Maron DJ**, Lasko TA. Machine learning for risk prediction of acute coronary syndrome. *AMIA Annu Symp Proc* 2014;2014:1940-9.
 56. Bradley SM, Chan PS, Hartigan PM, Nallamothu BK, Weintraub WS, Sedlis SP, Dada M, **Maron DJ**, Kostuk WJ, Berman DS, Teo KK, Mancini GBJ, Boden WE, Spertus JA. Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease.
 57. Collins SP, Jenkins CA, Harrell FE, Liu D, Miller KF, Lindsell CJ, Naftilan AJ, McPherson JA, **Maron DJ**, Sawyer DB, Weintraub NL, Fermann GJ, Roll SN, Sperling MA, Storrow AB. Identification of Emergency Department Patients with Acute Heart Failure at Low-Risk for 30-Day Adverse Events (The STRATIFY Decision Tool) *JACC Heart Fail*. 2015 3:737-47.
 58. Padala SK, Sidhu MS, Hartigan PM, **Maron DJ**, Teo KK, Spertus JA, Mancini GB, Sedlis SP, Chaitman BR, Heller GV, Weintraub WS, Boden WE. Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease: a post hoc analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial. *Am J Cardiol* 2015 2015;116:1509-15.
 59. Sedlis SP, Hartigan PM, Teo KK, **Maron DJ**, Spertus JA, Mancini GBJ, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE. Effect of PCI on long-term survival in patients with stable ischemic heart disease. *N Engl J Med* 2015;373:1937-46.
 60. Acharjee S, Teo KK, Jacobs AK, Hartigan PM, Barn K, Gosselin G, Tanguay J-F, **Maron DJ**, Kostuk WJ, Chaitman BR, Mancini GBJ, Spertus JA, Dada MR, Bates E, Booth DC, Weintraub WS, O'Rourke RA, Boden WE. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. *Am Heart J* 2016;173:108-17.
 61. Rodriguez F, Lin S, **Maron DJ**, Knowles JW, Virani SS, Heidenreich PA. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. *Am Heart J* 2016;182:97-102.
 62. Rodriguez F, **Maron DJ**, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol* 2017;2:47-54.
 63. Patel MR, Calhoun JH, Dehmer GJ, Grantham JA, Maddox TM, **Maron DJ**, Smith PK. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate use criteria for coronary revascularization in patients with acute coronary syndromes: a

- report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. *J Am Coll Cardiol* 2017;69:570-591.
64. Lui GK, Rogers IS, Ding VY, Hedlin HK, MacMillen K, **Maron DJ**, Sillman C, Romfh A, Dade TC, Haefele C, Grady SR, McElhinney DB, Murphy DJ, Fernandes SM. Risk estimates for atherosclerotic cardiovascular disease in adults with congenital heart disease. *Am J Cardiol* 2017;119:112-118.
 65. Patel MR, Calhoun JH, Dehmer GJ, Grantham JA, Maddox TM, **Maron DJ**, Smith PK. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. *J Am Coll Cardiol* 2017;69:2212-2241.
 66. Bagai A, Alexander KP, Berger JS, Senior R, Sajeev C, Pracon R, Mavromatis K, Lopez-Sendón JL, Gosselin G, Diaz A, Perna G, Drozdz J, Humen D, Petrauskiene B, Cheema AN, Phaneuf D, Banerjee S, Miller TD, Kedev S, Schuchlenz H, Stone GW, Goodman SG, Mahaffey KW, Jaffe AS, Rosenberg YD, Bangalore S, Newby LK, **Maron DJ**, Hochman JS, Chaitman BR. Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. *Am Heart J* 2017;190:135-139.
 67. Reaven GM, Knowles JW, Leonard D, Barlow CE, Willis BL, Haskell WL, **Maron DJ**. Relationship between simple markers of insulin resistance and coronary artery calcification. *J Clin Lipidol* 2017;11:1007-1012.
 68. Shah NS, Leonard D, Finley CE, Rodriguez F, Sarraju A, Barlow CE, DeFina LF, Willis BL, Haskell WL, **Maron DJ**. Dietary patterns and long-term survival: a retrospective study of healthy primary care patients. *Am J Med.* 2018;131:48-55.
 69. Zhang Z, Jones P, Weintraub WS, Mancini GBJ, Sedlis S, **Maron DJ**, Teo K, Hartigan P, Kostuk W, Berman D, Boden WE, Spertus JA. Predicting the benefits of percutaneous coronary intervention on 1-year angina and quality of life in stable ischemic heart disease: risk models from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). *Circ Cardiovasc Qual Outcomes* 2018;11:e003971. DOI: 10.1161/CIRCOUTCOMES.117.003971
 70. ISCHEMIA Trial Research Group. **Maron DJ**, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, MD, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson Jr. TB, Williams DO, Harrington RA, Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial: Rationale and Design. *Am Heart J* 2018;201:124-135.
 71. Rodriguez F, Knowles JW, **Maron DJ**, Virani SS, Heidenreich PA. Frequency of statin use in patients with low-density lipoprotein cholesterol ≥ 190 mg/dl from the Veterans Affairs Health System. *Am J Cardiol* 2018;311:80-89.
 72. Scudeler TL, Hueb WA, Farkouh ME, **Maron DJ**, Coelho de Soárez P, Campolina AG, Emy Takiuti ME, Rezende PC, Godoy LC, Hueb AC, Lima EG, Garzillo CL, Ramires JAF, Filho RK. Cost-effectiveness of on-pump and off-pump coronary

- artery bypass grafting for patients with coronary artery disease: results from the MASS III trial. *Int J Cardiol* 2018;273:63-68.
73. Bangalore S, **Maron DJ**, Fleg JL, O'Brien SM, Herzog CA, Stone GW, Mark DB, Spertus JA, Alexander KP, Sidhu MS, Chertow GM, Boden WE, Hochman JS; ISCHEMIA-CKD Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. *Am Heart J* 2018;205:42-52.
 74. **Maron DJ**, Mancini GBJ, Hartigan PM, Spertus JA, Sedlis SP, Kostuk WJ, Berman DS, Teo KK, Weintraub WS, Boden WE. Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. *J Am Coll Cardiol* 2018;72:2297-2305.
 75. Rodriguez F, Leonard D, DeFina L, Barlow CE, Willis BL, Haskell WL, **Maron DJ**. Association of educational attainment and cardiovascular risk in Hispanic individuals: Findings from the Cooper Center Longitudinal Study. *JAMA Cardiol* 2019;4:43-50.
 76. Rodriguez F, **Maron DJ**, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence with Mortality in Patients with Atherosclerotic Cardiovascular Disease. *JAMA Cardiol* 2019;4:206-213.
 77. Weintraub WS, Hartigan PM, Mancini GBJ, Teo KK, **Maron DJ**, Spertus JA, Chaitman BR, Shaw LJ, Berman DS, Boden WE. Effect of coronary anatomy and myocardial ischemia on long-term survival in patients with stable ischemic heart disease. *Circ Cardiovasc Qual Outcomes* 2019;12:e005079. DOI: 10.1161/CIRCOUTCOMES.118.005079.
 78. Hochman JS, Reynolds HR, Bangalore S, O'Brien S, Alexander K, Senior R, Boden W, Stone G, Goodman S, Lopes R, Lopez-Sendon J, White H, Maggioni A, Shaw L, Min J, Picard M, Berman D, Chaitman B, Mark D, Spertus J, Cyr D, Bhargava B, Ruzyllo W, Wander G, Chernyavskiy A, Rosenberg Y, **Maron DJ**. Baseline characteristics of participants in the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). *JAMA Cardiol* 2019;4:273-286.
 79. Mancini GBJ, **Maron DJ**, Hartigan PM, Spertus JA, Kostuk WJ, Berman DS, Teo KK, Weintraub WS, Boden WE, for the COURAGE Trial Research Group. Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. *J Am Coll Cardiol* 2019;73:2049-58.
 80. Raygor V, Garcia L, **Maron DJ**, Morton JM. The comparative effect of Roux-en-Y gastric bypass and sleeve gastrectomy on 10-year and lifetime atherosclerotic cardiovascular disease risk. *Obes Surg* 2019;29:3111-3117.
 81. Newman JD, Alexander KP, Gu X, O'Brien SM, Boden WE, Govindan SC, Senior R, Moorthy N, Rezende PC, Demkow M, Lopez-Sendon JL, Bockeria O, Pandit N, Gosselin G, Stone PH, Spertus JA, Stone GW, Fleg JL, Hochman JS, **Maron DJ**. Baseline predictors of low-density lipoprotein cholesterol and systolic blood pressure goal attainment after 1 year in the ISCHEMIA trial. *Circ Cardiovasc Qual Outcomes*. 2019;12:e006002. doi: 10.1161/CIRCOUTCOMES.119.006002.
 82. Clarke SL, Reaven GM, Leonard D, Barlow CE, Haskell WL, Willis BL, DeFina L, Knowles JW, **Maron DJ**. Cardiorespiratory fitness, body-mass index, and markers of insulin resistance in apparently healthy women and men. *Am J Med* 2020 Jan 9. pii: S0002-9343(20)30009-7. doi: 10.1016/j.amjmed.2019.11.031. PMID: 31926863 DOI: <https://doi.org/10.1016/j.amjmed.2019.11.031>
 83. **Maron DJ**, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ,

- Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzylo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y, ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med.* 2020;382:1395-1407.
84. Bangalore S, **Maron DJ**, O'Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, Berger JS, Mathew RO, Bockeria O, Broderick S, Pracon R, Herzog CA, Huang Z, Stone GW, Boden WE, Newman JD, Ali ZA, Mark DB, Spertus JA, Alexander KP, Chaitman BR, Chertow GM, Hochman JS, ISCHEMIA-CKD Research Group. Management of coronary disease in patients with advanced kidney disease. *N Engl J Med.* 2020;382:1608-1618.
85. Spertus JA, Jones PG, **Maron DJ**, O'Brien SM, Reynolds HR, Rosenberg Y, Stone GW, Harrell FE Jr, Boden WE, Weintraub WS, Baloch K, Mavromatis K, Diaz A, Gosselin G, Newman JD, Mavromichalis S, Alexander KP, Cohen DJ, Bangalore S, Hochman JS, Mark DB, ISCHEMIA Research Group. Health-status outcomes with invasive or conservative care in coronary disease. *N Engl J Med.* 2020;382:1408-1419.
86. Spertus JA, Jones PG, **Maron DJ**, Mark DB, O'Brien SM, Fleg JL, Reynolds HR, Stone GW, Sidhu MS, Chaitman BR, Chertow GM, Hochman JS, Bangalore S, ISCHEMIA-CKD Research Group. Health status after invasive or conservative care in coronary and advanced kidney disease. *N Engl J Med.* 2020;382:1619-1628.
87. Reynolds HR, Shaw LJ, Min JK, Spertus JA, Chaitman BR, Berman DS, Picard MH, Kwong RY, Bairey-Merz CN, Cyr DD, Lopes RD, Lopez-Sendon JL, Held C, Szwed H, Senior R, Gosselin G, Nair RG, Elghamaz A, Bockeria O, Chen J, Chernyavskiy AM, Bhargava B, Newman JD, Hinc SB, Jaroch J, Hoyer A, Berger J, Boden WE, O'Brien SM, **Maron DJ**, Hochman JS; ISCHEMIA Research Group. Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients with moderate or severe ischemia: secondary analysis of the ISCHEMIA randomized clinical trial. *JAMA Cardiol.* 2020;5:773-786.
88. Sarraju A, **Maron DJ**, Rodriguez F. Under-Reporting and under-representation of racial/ethnic minorities in major atrial fibrillation clinical trials. *JACC Clin Electrophysiol.* 2020;6:739-741.
89. Arges K, Assimes T, Bajaj V, Balu S, Bashir MR, Beskow L, Blanco R, Califf R, Campbell P, Carin L, Christian V, Cousins S, Das M, Dockery M, Douglas PS, Dunham A, Eckstrand J, Fleischmann D, Ford E, Fraulo E, French J, Gambhir SS, Ginsburg GS, Green RC, Haddad F, Hernandez A, Hernandez J, Huang ES, Jaffe G, King D, Kowek LH, Langlotz C, Liao YJ, Mahaffey KW, Marcom K, Marks WJ Jr, **Maron D***, McCabe R, McCall S, McCue R, Mega J, Miller D, Muhlbaier LH, Munshi R, Newby LK, Pak-Harvey E, Patrick-Lake B, Pencina M, Peterson ED, Rodriguez F, Shore S, Shah S, Shipes S, Sledge G, Spielman S, Spitler R, Schaack T, Swamy G, Willemink MJ, Wong CA. The Project Baseline Health Study: a step towards a broader mission to map human health. *NPJ Digit Med.* 2020;3:84. doi: 10.1038/s41746-020-0290-y. PMID: 32550652; PMCID: PMC7275087.
- *Participated extensively in study design and critical revision of the manuscript for important intellectual content.*

90. Bangalore S, **Maron DJ***, Stone GW, Hochman JS. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. *Circulation*. 2020;142:841-857. **Participated extensively in critical revision of the manuscript for important intellectual content.*
91. Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL, Rockhold FW, Elghamaz A, Lopez-Sendon JL, Farsky PS, Chernyavskiy AM, Diaz A, Phaneuf D, DeBelder MA, Ma YT, Guzman LA, Khouri M, Sionis A, Hausenloy DJ, Doerr R, Selvanayagam JK, Maggioni AP, Hochman JS, **Maron DJ**. Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial. *Circulation*. 2020;142:1725-1735.
92. Boden WE, Hartigan PM, Mancini J, Teo KK, Chaitman BR, **Maron DJ***, Kostuk WJ, Hartigan JA, Dada M, Spertus JA, Bates ER, Weintraub WS. Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients with Stable Coronary Artery Disease. *Am J Cardiol*. 2020;130:1-6. **Participated extensively in critical revision of the manuscript for important intellectual content.*
93. Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Perna GP, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, **Maron DJ¹**, Hochman JS; ISCHEMIA Research Group. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. *Circulation* 2021;143:790-804.
94. Mancini GBJ, Leipsic J, Budoff MJ, Hague CJ, Min JK, Stevens SR, Reynolds HR, O'Brien SM, Shaw LJ, Manjunath CN, Mavromatis K, Demkow M, Lopez-Sendon JL, Chernavskiy AM, Gosselin G, Schuchlenz H, Devlin GP, Chauhan A, Bangalore S, Hochman JS, **Maron DJ**. Coronary CT Angiography Followed by Invasive Angiography in Patients with Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. *JACC Cardiovasc Imaging*. 2021 Jan 7:S1936-878X(20)31019-6. doi: 10.1016/j.jcmg.2020.11.012.
95. White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li J, Manjunath CN, Lopez-Sendon JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, **Maron DJ**. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. *JAMA Cardiol*. 2021 May 3. doi: 10.1001/jamacardio.2021.1651.
96. Herzog CA, Simegn MA, Xu Y, Costa SR, Mathew RO, El-Hajjar MC, Gulati S, Maldonado RA, Daugas E, Madero M, Fleg JL, Anthopolos R, Stone GW, Sidhu MS, **Maron DJ²**, Hochman JS, Bangalore S. Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. *J Am Coll Cardiol*. 2021 May 4;S0735-1097(21)04965-2. doi: 10.1016/j.jacc.2021.05.001.
97. Reynolds HR, Picard MH, Spertus JA, Peteiro J, Lopez-Sendon JL, Senior R, El-Hajjar MC, Celutkiene J, Shapiro MD, Pellikka PA, Kunichoff DF, Anthopolos R, Alfakih K, Abdul-Nour K, Khouri M, Bershtein L, De Belder M, Poh KK, Beltrame JF, Min JK, Fleg JL, Li Y, **Maron DJ¹**, Hochman JS. Natural History of Patients with Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. *Circulation*. 2021 Jun 1. doi: 10.1161/CIRCULATIONAHA.120.046791. Online ahead of print.
98. Eng D, Chute C, Khandwala N, Rajpurkar P, Long J, Shleifer S, Khalaf MH, Sandhu AT, Rodriguez F, **Maron DJ***, Seyyedi S, Marin D, Golub I, Budoff M, Kitamura F, Takahashi MS, Filice RW, Shah R, Mongan J, Kallianos K, Langlotz CP, Lungren

- MP, Ng AY, Patel BN. Automated coronary calcium scoring using deep learning with multicenter external validation. *npj Digit Med*. 2021;4:88. doi: 10.1038/s41746-021-00460-1. **Responsible for the idea to create an automated coronary calcium scoring algorithm. Participated extensively in critical revision of the manuscript for important intellectual content.*
99. Sarraju A, Valencia A, Knowles JW, **Maron DJ***, Rodriguez F. Diverse Racial/Ethnic Group Underreporting and Underrepresentation in High-Impact Cholesterol Treatment Trials. *Circulation*. 2021;143:2409-2411. **Participated extensively in critical revision of the manuscript for important intellectual content.*
 100. Sandhu AT, Tisdale RL, Rodriguez F, Stafford RS, **Maron DJ***, Hernandez-Boussard T, Lewis E, Heidenreich PA. Disparity in the Setting of Incident Heart Failure Diagnosis. *Circ Heart Fail*. 2021 Aug;14(8):e008538. doi: 10.1161/CIRCHEARTFAILURE.121.008538. Epub 2021 Jul 27. **Participated extensively in critical revision of the manuscript for important intellectual content.*
 101. Reynolds HR, Shaw LJ, Min JK, Page CB, Berman DS, Chaitman BR, Picard MH, Kwong RY, O'Brien SM, Huang Z, Mark DB, Nath RK, Dwivedi SK, Smanio PEP, Stone PH, Held C, Keltai M, Bangalore S, Newman JD, Spertus JA, Stone GW, **Maron DJ¹**, Hochman JS. Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. *Circulation*. 2021 Sep 9;. doi: 10.1161/CIRCULATIONAHA.120.049755. [Epub ahead of print] PubMed PMID: 34496632.
 102. Lopez-Sendon JL, Cyr DD, Mark DB, Bangalore S, Huang Z, White HD, Alexander KP, Li J, Nair RG, Demkow M, Peteiro J, Wander GS, Demchenko EA, Gamma R, Gadkari M, Poh KK, Nageh T, Stone PH, Keltai M, Sidhu M, Newman JD, Boden WE, Reynolds HR, Chaitman BR, Hochman JS, **Maron DJ¹**, O'Brien SM. Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. *Eur Heart J*. 2021 Sep 13;. doi: 10.1093/eurheartj/ehab509. [Epub ahead of print] PubMed PMID: 34514494.
 103. Newman JD, Anthopolos R, Mancini GBJ, Bangalore S, Reynolds HR, Kunichoff DF, Senior R, Peteiro J, Bhargava B, Garg P, Escobedo J, Doerr R, Mazurek T, Gonzalez-Juanatey J, Gajos G, Briguori C, Cheng H, Vertes A, Mahajan S, Guzman LA, Keltai M, Maggioni AP, Stone GW, Berger JS, Rosenberg YD, Boden WE, Chaitman BR, Fleg JL, Hochman JS, **Maron DJ**. Outcomes of Participants with Diabetes in the ISCHEMIA Trials. *Circulation*. 2021 Sep 15;. doi: 10.1161/CIRCULATIONAHA.121.054439. [Epub ahead of print] PubMed PMID: 34521217.
 104. Baine KR, Fleg JL, Hochman JS, Kunichoff DF, Anthopolos R, Chernyavskiy AM, Demkow M, Lopez-Quijano JM, Escobedo J, Poh KK, Ramos RB, Lima EG, Schuchlenz H, Ali ZA, Stone GW, **Maron DJ²**, O'Brien SM, Spertus JA, Bangalore S. Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia. *Am Heart J*. 2022;243:187-200. PMID: 34582775
 105. Sidhu MS, Alexander KP, Huang Z, O'Brien SM, Chaitman BR, Stone GW, Newman JD, Boden WE, Maggioni AP, Steg PG, Ferguson TB, Demkow M, Peteiro J, Wander GS, Phaneuf DC, De Belder MA, Doerr R, Alexanderson-Rosas E, Polanczyk CA, Henriksen PA, Conway DSG, Miro V, Sharir T, Lopes RD, Min JK, Berman DS, Rockhold FW, Balter S, Borrego D, Rosenberg YD, Bangalore S, Reynolds HR, Hochman JS, **Maron DJ**; ISCHEMIA Research Group. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. *Am Heart J*. 2022;248:72-83. doi: 10.1016/j.ahj.2022.01.017. Epub ahead of print. PMID: 35149037.

106. Mark DB, Spertus JA, Bigelow R, Anderson S, Daniels MR, Anstrom KJ, Baloch KN, Cohen DJ, Held C, Goodman SG, Bangalore S, Cyr D, Reynolds HR, Alexander KP, Rosenberg Y, Stone GW, **Maron DJ**¹, Hochman JS; ISCHEMIA Research Group. Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. *Circulation*. 2022 Mar 9. doi: 10.1161/CIRCULATIONAHA.121.057363.
107. Briguori C, Mathew RO, Huang Z, Mavromatis K, Hickson LJ, Lau WL, Mathew A, Mahajan S, Wheeler DC, Claes KJ, Chen G, Nolasco FEB, Stone GW, Fleg JL, Sidhu MS, Rockhold FW, Chertow GM, Hochman JS, **Maron DJ**², Bangalore S. Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. *J Am Heart Assoc*. 2022 Mar 9:e022003. doi: 10.1161/JAHA.121.022003.
108. Senior R, Reynolds HR, Min JK, Berman DS, Picard MH, Chaitman BR, Shaw LJ, Page CB, Govindan SC, Lopez-Sendon J, Peteiro J, Wander GS, Drozd J, Marin-Neto J, Selvanayagam JB, Newman JD, Thuaisne C, Christopher J, Jang JJ, Kwong RY, Bangalore S, Stone GW, O'Brien SM, Boden WE, **Maron DJ**¹, Hochman JS; ISCHEMIA Research Group. Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. *J Am Coll Cardiol*. 2022 Feb 22;79(7):651-661. doi: 10.1016/j.jacc.2021.11.052.
109. Bangalore S, Spertus JA, Stevens SR, Jones PG, Mancini GBJ, Leipsic J, Reynolds HR, Budoff MJ, Hague CJ, Min JK, Boden WE, O'Brien SM, Harrington RA, Berger JS, Senior R, Peteiro J, Pandit N, Bershtein L, de Belder MA, Szwed H, Doerr R, Monti L, Alfaqih K, Hochman JS, **Maron DJ**; ISCHEMIA Research Group. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. *Circ Cardiovasc Interv*. 2022 Apr 12:CIRCINTERVENTIONS121010925. doi: 10.1161/CIRCINTERVENTIONS.121.010925. Online ahead of print. PMID: 35411785
110. Haisum Maqsood M, Messerli FH, Waters D, Skolnick AH, **Maron DJ**^{*}, Bangalore S. Timing of Statin Dose: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *Eur J Prev Cardiol*. 2022 May 5:zwac085. doi: 10.1093/eurjpc/zwac085. Online ahead of print. PMID: 35512427 **Participated extensively in critical revision of the manuscript for important intellectual content.*
111. Haddad F, Cauwenberghs N, Daubert MA, Kobayashi Y, Bloomfield GS, Fleischman D, Koweek L, **Maron DJ**^{*}, Rodriguez F, Liao YJ, Moneghetti K, Amsallem M, Mega J, Hernandez A, Califf R, Mahaffey KW, Shah SH, Kuznetsova T, Douglas PS; Project Baseline Health Study Investigators. Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study. *J Cardiovasc Comput Tomogr*. 2022 Jul 5:S1934-5925(22)00101-0. doi: 10.1016/j.jcct.2022.06.003. Online ahead of print. PMID: 35872137 **Participated extensively in critical revision of the manuscript for important intellectual content.*
112. Rodriguez, F, Hochman, JS, Xu, Y, Reynolds, H, Berger, J, Mavromichalis, S, Newman J, Bangalore S, **Maron, DJ**. Screening for participants in the ISCHEMIA trial: Implications for clinical research. *Journal of Clinical and Translational Science*, 6(1), E90. doi:10.1017/cts.2022.428.
113. Chatterjee R, Kwee LC, Pagidipati N, Koweek LH, Mettu PS, Haddad F, **Maron DJ**^{*}, Rodriguez F, Mega JL, Hernandez A, Mahaffey K, Palaniappan L, Shah SH; Project Baseline Health Study. Multi-dimensional characterization of prediabetes in the Project Baseline Health Study. *Cardiovasc Diabetol*. 2022 Jul 18;21(1):134. doi: 10.1186/s12933-022-01565-x. PMID: 35850765. **Participated extensively in critical revision of the manuscript for important intellectual content.*

114. Smilowitz NR, Carey EP, Shah B, Hartigan PM, Plomondon ME, **Maron DJ***, Maddox TM, Spertus JA, Mancini GBJ, Chaitman BR, Weintraub WS, Sedlis SP, Boden WE; COURAGE Trial Investigators and VA CART CL. Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. *Am J Cardiol.* 2022 Jul 30:S0002-9149(22)00699-3. doi: 10.1016/j.amjcard.2022.06.049. Online ahead of print. PMID: 35918234
**Participated extensively in critical revision of the manuscript for important intellectual content.*
115. Bangalore S, Hochman JS, Stevens SR, Jones PG, Spertus JA, O'Brien SM, Reynolds HR, Boden WE, Fleg JL, Williams DO, Stone GW, Sidhu MS, Mathew RO, Chertow GM, **Maron DJ.** Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients with Chronic Coronary Disease Across the Spectrum of Kidney Function. *JAMA Cardiol.* 2022 Aug 1;7(8):825-835. doi: 10.1001/jamacardio.2022.1763. PMID: 35767253.
116. Garcia RA, Spertus JA, Benton MC, Jones PG, Mark DB, Newman JD, Bangalore S, Boden WE, Stone GW, Reynolds HR, Hochman JS, **Maron DJ.** Association of Medication Adherence with Health Outcomes in the ISCHEMIA Trial. *J Am Coll Cardiol.* 2022 Aug, 80 (8) 755–765. <https://doi.org/10.1016/j.jacc.2022.05.045>
117. Reynolds HR, Diaz A, Cyr DD, Shaw LJ, Mancini GBJ, Leipsic J, Budoff MJ, Min JK, Hague CJ, Berman DS, Chaitman BR, Picard MH, Hayes SW, Scherrer-Crosbie M, Kwong RY, Lopes RD, Senior R, Dwivedi SK, Miller TD, Chow BJW, de Silva R, Stone GW, Boden WE, Bangalore S, O'Brien SM, Hochman JS, **Maron DJ;** ISCHEMIA Research Group. Ischemia With Nonobstructive Coronary Arteries: Insights From the ISCHEMIA Trial. *JACC Cardiovasc Imaging.* 2022 Sep 13:S1936-878X(22)00406-5. doi: 10.1016/j.jcmg.2022.06.015. Online ahead of print. PMID: 36115814
118. Mathew RO, **Maron DJ**², Anthopolos R, Fleg JL, O'Brien SM, Rockhold FW, Briguori C, Roik MF, Mazurek T, Demkow M, Malecki R, Ye Z, Kaul U, Miglinas M, Stone GW, Wald R, Charytan DM, Sidhu MS, Hochman JS, Bangalore S. Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. 2022. *Circ Cardiovasc Qual Outcomes.* 2022 Oct 4:101161CIRCOUTCOMES122008995. doi: 10.1161/CIRCOUTCOMES.122.008995. Online ahead of print. PMID: 36193750
119. Anthopolos R, **Maron DJ**¹, Bangalore S, Reynolds HR, Xu Y, O'Brien SM, Troxel AB, Mavromichalis S, Chang M, Contreras A, Hochman JS, ISCHEMIA-EXTEND Research Group. ISCHEMIA-EXTEND Studies: Rationale and Design. *Am Heart J* 2022. DOI 10.1016/j.ahj.2022.09.009. PubMedID 36206950.
120. Sandhu AT, Rodriguez F, **Maron DJ***, Heidenreich PA. Use of lipid-lowering therapy preceding first hospitalization for acute myocardial infarction or stroke. *Am J Prev Cardiol.* 2022 Oct 8;12:100426. doi: 10.1016/j.ajpc.2022.100426. PMID: 36304918; PMCID: PMC9593274. **Participated extensively in critical revision of the manuscript for important intellectual content.*
121. Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, Mavromichalis S, Chang M, Contreras A, Rosenberg Y, Kirby R, Bhargava B, Senior R, Banfield A, Goodman SG, Lopes RD, Pracon R, López-Sendón J, Maggioni AP, Newman JD, Berger JS, Sidhu MS, White HD, Troxel AB, Harrington RA, Boden WE, Stone GW, Mark DB, Spertus JA, **Maron DJ;** ISCHEMIA-EXTEND Research Group. Survival After Invasive or Conservative Management of Stable Coronary

- Disease. *Circulation*. 2023 Jan 3;147(1):8-19. doi: 10.1161/CIRCULATIONAHA.122.062714. Epub 2022 Nov 6. PMID: 36335918; PMCID: PMC9797439.
122. Sandhu AT, Rodriguez F, Ngo S, Patel BN, Mastrodicasa D, Eng D, Khandwala N, Balla S, Sousa D, **Maron DJ**. Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project). *Circulation*. 2023 Feb 28;147(9):703-714. doi: 10.1161/CIRCULATIONAHA.122.062746. Epub 2022 Nov 7. PMID: 36342823; PMCID: PMC10108579.
 123. Vasti EC, Basina M, Calma J, **Maron DJ***, Rodriguez F, Sandhu AT. Disparities in Adoption of New Diabetic Therapies with Cardiovascular Benefits. *Diabetes Res Clin Pract*. 2022 Dec 26:110233. doi: 10.1016/j.diabres.2022.110233. Epub ahead of print. PMID: 36581144. **Participated extensively in critical revision of the manuscript for important intellectual content.*
 124. Sidhu MS, Alexander KP, Huang Z, Mathew RO, Newman JD, O'Brien SM, Pellikka PA, Lyubarova R, Bockeria O, Briguori C, Kretov EL, Mazurek T, Orso F, Roik MF, Sajeev C, Shutov EV, Rockhold FW, Borrego D, Balter S, Stone GW, Chaitman BR, Goodman SG, Fleg JL, Reynolds HR, **Maron DJ²**, Hochman JS, Bangalore S; ISCHEMIA-CKD Research Group. Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial. *JACC Cardiovasc Interv*. 2023 Jan 23;16(2):209-218. doi: 10.1016/j.jcin.2022.10.062. PMID: 36697158.
 125. Tisdale RL, Fan J, Calma J, Cyr K, Podchiyska T, Stafford RS, **Maron DJ***, Hernandez-Boussard T, Ambrosy A, Heidenreich PA, Sandhu AT. Predictors of Incident Heart Failure Diagnosis Setting: Insights from the Veterans Affairs Healthcare System. *JACC Heart Fail*. 2023 Mar;11(3):347-358. doi: 10.1016/j.jchf.2022.11.013. Epub 2023 Feb 1. PMID: 36881392; PMCID: PMC10069381. **Participated extensively in critical revision of the manuscript for important intellectual content.*
 126. Nguyen DD, Spertus JA, Alexander KP, Newman JD, Dodson JA, Jones PG, Stevens SR, O'Brien SM, Gamma R, Perna GP, Garg P, Vitola JV, Chow BJW, Vertes A, White HD, Smanio PEP, Senior R, Held C, Li J, Boden WE, Mark DB, Reynolds HR, Bangalore S, Chan PS, Stone GW, Arnold SV, **Maron DJ¹**, Hochman JS; ISCHEMIA Research Group. Health Status and Clinical Outcomes in Older Adults with Chronic Coronary Disease: The ISCHEMIA Trial. *J Am Coll Cardiol*. 2023 May 2;81(17):1697-1709. doi: 10.1016/j.jacc.2023.02.048. PMID: 37100486.
 127. Stone GW, Ali ZA, O'Brien SM, Rhodes G, Genereux P, Bangalore S, Mavromatis K, Horst J, Dressler O, Poh KK, Nath RK, Moorthy N, Witkowski A, Dwivedi SK, Bockeria O, Chen J, Smanio PEP, Picard MH, Chaitman BR, Berman DS, Shaw LJ, Boden WE, White HD, Fremes SE, Rosenberg Y, Reynolds HR, Spertus JA, Hochman JS, **Maron DJ**; ISCHEMIA Research Group. Impact of Complete Revascularization in the ISCHEMIA Trial. *J Am Coll Cardiol*. 2023 Jul 11:S0735-1097(23)06031-X. doi: 10.1016/j.jacc.2023.06.015. Epub ahead of print. PMID: 37462593.
 128. Mavromatis K, Jones PG, Ali ZA, Stone GW, Rhodes GM, Bangalore S, O'Brien S, Genereux P, Horst J, Dressler O, Goodman S, Alexander K, Mathew A, Chen J, Bhargava B, Uxa A, Boden WE, Mark DB, Reynolds HR, **Maron DJ¹**, Hochman JS, Spertus JA; ISCHEMIA Research Group. Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial. *J Am Coll Cardiol*. 2023 Jul 25;82(4):295-313. doi: 10.1016/j.jacc.2023.05.025. PMID: 37468185.

129. Newman JD, Anthopolos R, Ruggles KV, Cornwell M, Reynolds HR, Bangalore S, Mavromatis K, Held C, Wallentin L, Kullo IJ, McManus B, Newby LKK, Rosenberg Y, Hochman JS, **Maron DJ**¹, Berger JS; ISCHEMIA Biorepository Research Group. Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials: Biomarkers and risk prediction in stable coronary artery disease. A post-hoc secondary analysis from the ISCHEMIA randomized clinical trial biorepository. *Am Heart J.* 2023 Aug 19;S0002-8703(23)00204-1. doi: 10.1016/j.ahj.2023.08.007. Epub ahead of print. PMID: 37604357.
130. Peng AW, Dudum R, Jain SS, **Maron DJ**^{*}, Patel BN, Khandwala N, Eng D, Chaudhari AS, Sandhu AT, Rodriguez F. Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging with Cardiovascular Outcomes. *J Am Coll Cardiol.* 2023 Sep 19;82(12):1192-1202. doi: 10.1016/j.jacc.2023.06.040. PMID: 37704309. **Participated extensively in developing the concept and design of this study, and critical revision of the manuscript for important intellectual content.*
131. Ngo S, Asirvatham R, Baird GL, Sarraju A, **Maron DJ**^{*}, Rodriguez F. Readability and reliability of online patient education materials about statins. *Am J Prev Cardiol.* 2023 Sep 29;16:100594. doi: 10.1016/j.ajpc.2023.100594. PMID: 37822580; PMCID: PMC10562660. **Participated extensively in critical revision of the manuscript for important intellectual content.*
132. Mathew RO, Kretov EI, Huang Z, Jones PG, Sidhu MS, O'Brien SM, Prokhorikhin AA, Rangaswami J, Newman J, Stone GW, Fleg JL, Spertus JA, **Maron DJ**², Hochman JS, Bangalore S; ISCHEMIA-CKD Research Group. BMI and Clinical and Health Status Outcomes in Chronic Coronary Disease and Advanced Kidney Disease in ISCHEMIA-CKD. *Am J Med.* 2023 Nov 2;S0002-9343(23)00674-5. doi: 10.1016/j.amjmed.2023.10.024. Epub ahead of print. PMID: 37925061.
133. Zambrano Chaves JM, Wentland AL, Desai AD, Banerjee I, Kaur G, Correa R, Boutin RD, **Maron DJ**^{*}, Rodriguez F, Sandhu AT, Rubin D, Chaudhari AS, Patel BN. Opportunistic assessment of ischemic heart disease risk using abdominopelvic computed tomography and medical record data: a multimodal explainable artificial intelligence approach. *Sci Rep.* 2023 Nov 29;13(1):21034. doi: 10.1038/s41598-023-47895-y. PMID: 38030716; PMCID: PMC10687235. **Participated in critical revision of the manuscript for important intellectual content.*
134. Reynolds HR, Cyr DD, Merz CNB, Shaw LJ, Chaitman BR, Boden WE, Alexander KP, Rosenberg YD, Bangalore S, Stone GW, Held C, Spertus J, Goetschalekx K, Bockeria O, Newman JD, Berger JS, Elghamaz A, Lopes RD, Min JK, Berman DS, Picard MH, Kwong RY, Harrington RA, Thomas B, O'Brien SM, **Maron DJ**¹, Hochman JS; ISCHEMIA Research Group. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients with Chronic Coronary Disease: Insights From the ISCHEMIA Trial. *J Am Heart Assoc.* 2024 Mar 5;13(5):e029850. doi: 10.1161/JAHA.122.029850. Epub 2024 Feb 27. PMID: 38410945; PMCID: PMC10944079.
135. Leipsic J, Ben Zekry S, Tzimas G, Broderick S, Mancini GBJ, Hague CJ, Budoff MJ, Rockhold FW, Chaitman BR, Kirby R, Stone GW, Ali ZA, Min JK, Hochman JS, **Maron DJ**¹, Reynolds HR; ISCHEMIA Research Group. Comparative Prognostic Utility of Coronary CT and Invasive Angiography: Insights From the ISCHEMIA Trial. *JACC Cardiovasc Imaging.* 2024 Mar 4;S1936-878X(24)00067-6. doi: 10.1016/j.jcmg.2023.11.015. Epub ahead of print. PMID: 38483421.
136. Somani S, Balla S, Peng AW, Dudum R, Jain S, Nasir K, **Maron DJ**^{*}, Hernandez-Boussard T, Rodriguez F. Contemporary attitudes and beliefs on coronary artery calcium from social media using artificial intelligence. *NPJ Digit Med.* 2024 Mar

- 30;7(1):83. doi: 10.1038/s41746-024-01077-w. PMID: 38555387; PMCID: PMC10981728. **Participated in critical revision of the manuscript for important intellectual content.*
137. Arnold SV, Jones PG, **Maron DJ**¹, Cohen DJ, Mark DB, Reynolds HR, Bangalore S, Chen J, Newman JD, Harrington RA, Stone GW, Hochman JS, Spertus JA; ISCHEMIA Research Group. Variation in Health Status With Invasive vs Conservative Management of Chronic Coronary Disease. *J Am Coll Cardiol.* 2024 Apr 16;83(15):1353-1366. doi: 10.1016/j.jacc.2024.02.019. PMID: 38599711.
138. Nurmohamed NS, van Rosendael AR, Danad I, Ngo-Metzger Q, Taub PR, Ray KK, Figtree G, Bonaca MP, Hsia J, Rodriguez F, Sandhu AT, Nieman K, Earls JP, Hoffmann U, Bax JJ, Min JK, **Maron DJ**^{*}, Bhatt DL. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. *Eur Heart J.* 2024 Apr 12;ehae190. doi: 10.1093/eurheartj/ehae190. Epub ahead of print. PMID: 38606889. **Participated in critical revision of the manuscript for important intellectual content.*
139. Pracoń R, Spertus JA, Broderick S, Bangalore S, Rockhold FW, Ruzyllo W, Demchenko E, Nageh T, Grossman GB, Mavromatis K, Manjunath CN, Smanio PEP, Stone GW, Mancini GBJ, Boden WE, Newman JD, Reynolds HR, Hochman JS, **Maron DJ**; ISCHEMIA Research Group. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative c10.1161/CIRCINTERVENTIONS.123.013435. Epub ahead of print. PMID: 38629312.
140. Ikemura N, Spertus JA, Nguyen D, Fu Z, Jones PG, Reynolds HR, Bangalore S, Bhargava B, Senior R, Elghamaz A, Goodman S, Lopes RD, Pracoń R, López-Sendón J, Maggioni AP, Kohsaka S, Roth GA, White HD, Mavromatis K, Boden WE, Rodriguez F, Hochman JS, **Maron DJ**, on behalf of the ISCHEMIA Research Group. International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights from the ISCHEMIA trial. *Circ Cardiovasc Qual Outcomes.* 2024;17:e010534. DOI: 10.1161/CIRCOUTCOMES.123.010534.
141. Hamo CE, Liu R, Wu W, Anthopolos R, Bangalore S, Held C, Kullo I, Mavromatis K, McManus B, Newby LK, Reynolds HR, Ruggles KV, Wallentin L, **Maron DJ**¹, Hochman JS, Newman JD, Berger JS, on behalf of the ISCHEMIA Biorepository Research Group. Cardiometabolic Comorbidity Burden and Circulating Biomarkers in Patients with Chronic Coronary Disease in the ISCHEMIA Trials. *Am J Cardiol.* 2024 Jun 4:S0002-9149(24)00416-8. doi: 10.1016/j.amjcard.2024.05.033. Epub ahead of print. PMID: 38844195.
142. Gupta A, Tisdale RL, Calma J, Stafford RS, **Maron DJ**^{*}, Hernandez-Boussard T, Ambrosy AP, Heidenreich PA, Sandhu AT. Equity in the Setting of Heart Failure Diagnosis: An Analysis of Differences Between and Within Clinician Practices. *Circ Heart Fail.* 2024 Jun 7:e010718. doi: 10.1161/CIRCHEARTFAILURE.123.010718. Epub ahead of print. PMID: 38847082. **Participated in critical revision of the manuscript for important intellectual content.*
143. Kercheval JB, Narcisse DI, Nguyen M, Rao SV, Gutierrez JA, Leeper NJ, **Maron DJ**^{*}, Rodriguez F, Hernandez AF, Mahaffey KW, Shah SH. Characterization of Peripheral Artery Disease and Associations with Traditional Risk Factors, Mobility, and Biomarkers in the Project Baseline Health Study. *Am Heart J.* 2024 Jul 3:S0002-8703(24)00164-9. doi: 10.1016/j.ahj.2024.06.010. Epub ahead of print. PMID: 38969081. **Participated in critical revision of the manuscript for important intellectual content.*

144. Nurmohamed NS, Min JK, Anthopolos R, Reynolds HR, Earls JP, Crabtree T, Mancini GBJ, Leipsic J, Budoff MJ, Hague CJ, O'Brien SM, Stone GW, Berger JS, Donnino R, Sidhu MS, Newman JD, Boden WE, Chaitman BR, Stone PH, Bangalore S, Spertus JA, Mark DB, Shaw LJ, Hochman JS, **Maron DJ**. Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. *Eur Heart J*. 2024 Aug 5:ehae471. doi: 10.1093/eurheartj/ehae471. Epub ahead of print. PMID: 39101625.
145. Fleg JL, Huang Z, Reynolds HR, Shaw LJ, Chaitman BR, O'Brien SM, Berstein L, Peteiro J, Smanio PEP, Wander GS, Berger JS, Berman DS, Picard MH, Kwong RY, Min JK, Phillips LM, Bangalore S, **Maron DJ**¹, Hochman JS; ISCHEMIA Research Group. Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA. *Circulation*. 2024 Jul 9;150(2):165-167. doi: 10.1161/CIRCULATIONAHA.123.066980. Epub 2024 Jul 8. PMID: 38976607; PMCID: PMC11232923.
146. Peng AW, Skye M, Jain SS, Dudum R, **Maron DJ***, Din N, Patel BN, Chaudhari AS, Sandhu AT, Rodriguez F. Sociodemographic Differences Among Patients Receiving Coronary Artery Calcium Imaging vs Nongated Chest Computed Tomography Imaging. *JACC Adv*. 2024 May 15;3(7):100963. doi: 10.1016/j.jacadv.2024.100963. PMID: 39129975; PMCID: PMC11312303.
**Participated extensively in developing the concept and design of this study, and critical revision of the manuscript for important intellectual content.*
147. Jain SS, Skye M, Din N, Furst A, **Maron DJ***, Heidenreich P, Kalwani N, Bhatt AS, Sandhu AT, Rodriguez F. Low-Density Lipoprotein Cholesterol Control as a Performance Measure: A National Analysis of the VHA. *J Am Coll Cardiol*. 2024 Sep 24;84(13):1272-1275. doi: 10.1016/j.jacc.2024.07.025. PMID: 39293887.
**Participated extensively in developing the concept and design of this study, and critical revision of the manuscript for important intellectual content.*
148. Ikemura N, Spertus JA, Nguyen D, Fu Z, Jones PG, Reynolds HR, Bangalore S, Bhargava B, Senior R, Elghamaz A, Goodman SG, Lopes RD, Pracoń R, López-Sendón J, Maggioni AP, Kohsaka S, Roth GA, White HD, Mavromatis K, Boden WE, Rodriguez F, Hochman JS, **Maron DJ**; ISCHEMIA Research Group. International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA Trial. *Circ Cardiovasc Qual Outcomes*. 2024 Sep 20:e010534. doi: 10.1161/CIRCOUTCOMES.123.010534. Epub ahead of print. PMID: 39301726.
149. Nguyen DD, Decker C, Pacheco CM, Farr SL, Fuss C, Masterson Creber RM, Pena S, Ikemura N, Uzendu AI, **Maron DJ**¹, Hochman JS, Dodson JA, Spertus JA. Developing an Individualized Patient Decision Aid for Chronic Coronary Disease Based on the ISCHEMIA Trial: A Mixed-Methods Study. *Circ Cardiovasc Qual Outcomes*. 2024 Sep 20:e010923. doi: 10.1161/CIRCOUTCOMES.124.010923. Epub ahead of print. PMID: 39301725.
150. Bangalore S, Rhodes G, **Maron DJ**¹, Anthopolos R, O'Brien SM, Jones PG, Mark DB, Reynolds HR, Spertus JA, Stone GW, White HD, Xu Y, Fremes SE, Hochman JS, Ischemia Research Group OBOT. Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial. *EuroIntervention*. 2024 Oct 21;20(20):e1276-e1287. doi: 10.4244/EIJ-D-24-00240. PMID: 39432255; PMCID: PMC11472139.
151. Gomez SE, Furst A, Chen T, Din N, **Maron DJ***, Heidenreich P, Kalwani N, Nallamshetty S, Ward JH, Lozama A, Sandhu A, Rodriguez F. Temporal trends in lipoprotein(a) testing among United States veterans from 2014 to 2023. *Am J Prev Cardiol*. 2024 Sep 23;20:100872. doi: 10.1016/j.ajpc.2024.100872. PMID: 39430431;

- PMCID: PMC11489823. **Participated in critical revision of the manuscript for important intellectual content.*
152. Naghavi M, Reeves AP, Atlas K, Zhang C, Atlas T, Henschke CI, Yankelevitz DF, Budoff MJ, Li D, Roy SK, Nasir K, Molloy S, Fayad Z, McConnell MV, Kakadiaris I, **Maron DJ***, Narula J, Williams K, Shah PK, Levy D, Wong ND. Artificial intelligence applied to coronary artery calcium scans (AI-CAC) significantly improves cardiovascular events prediction. NPJ Digit Med. 2024 Nov 5;7(1):309. doi: 10.1038/s41746-024-01308-0. PMID: 39501071; PMCID: PMC11538462. **Participated in critical revision of the manuscript for important intellectual content.*
 153. Geba GP, Chen R, Talapatra K, Brackin T, Mohammadi KA, Pordy R, Manvelian G, **Maron DJ***, Schwartz GG, Szarek M, Steg PG, Fazio S. Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES. Am J Prev Cardiol. 2024 Nov 26;20:100900. doi: 10.1016/j.ajpc.2024.100900. PMID: 39687787; PMCID: PMC11648769. **Participated in critical revision of the manuscript for important intellectual content.*
 154. Reynolds HR, Page CB, Shaw LJ, Berman DS, Chaitman BR, Picard MH, Kwong RY, Min JK, Leipsic J, Mancini GBJ, Budoff MJ, Hague CJ, Senior R, Szwed H, Bhargava B, Celutkienė J, Gadkari M, Bainey KR, Doerr R, Ramos RB, Ong P, Naik SR, Steg PG, Goetschalckx K, Chow BJW, Scherrer-Crosbie M, Phillips L, Mark DB, Spertus JA, Alexander KP, O'Brien SM, Boden WE, Bangalore S, Stone GW, **Maron DJ¹**, Hochman JS; ISCHEMIA Research Group. Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial. Circ Cardiovasc Interv. 2024 Dec;17(12):e013743. doi: 10.1161/CIRCINTERVENTIONS.123.013743. Epub 2024 Dec 17. PMID: 39689188; PMCID: PMC11658795.
 155. Chen T, Furst A, Din N, Gomez S, **Maron DJ***, Heidenreich P, Nallamshetty S, Kalwani N, Xu S, Ward JH, Lozama A, Sandhu A, Rodriguez F. Lipoprotein a Testing Patterns in the Veterans Health Administration. JAMA Netw Open. 2025 Jan 2;8(1):e2453300. doi: 10.1001/jamanetworkopen.2024.53300. PMID: 39745706; PMCID: PMC11696446. **Participated in critical revision of the manuscript for important intellectual content.*
 156. Hausvater A, Anthopolos R, Seltzer A, Spruill TM, Spertus JA, Peteiro J, Lopez-Sendon JL, Čelutkienė J, Demchenko EA, Kedev S, Beleslin BD, Sidhu MS, Grodzinsky A, Fleg JL, **Maron DJ¹**, Hochman JS, Reynolds HR; CIAO-ISCHEMIA Research Group. Sex Differences in Psychosocial Factors and Angina in Patients With Chronic Coronary Disease. J Am Heart Assoc. 2025 Feb 25:e037909. doi: 10.1161/JAHA.124.037909. Epub ahead of print. PMID: 39996455.
 157. Slater J, **Maron DJ¹**, Jones PG, Bangalore S, Reynolds HR, Fu Z, Stone GW, Kirby R, Hochman JS, Spertus JA; ISCHEMIA Research Group. Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data from the ISCHEMIA Trial. Circ Cardiovasc Qual Outcomes. 2025 Feb 26:e010849. doi: 10.1161/CIRCOUTCOMES.124.010849. Epub ahead of print. PMID: 40008421.
 158. Picard MH, Saysana K, Cyr DD, Zeng X, Scherrer-Crosbie M, Shaw LJ, Senior R, Poh KK, Bangalore S, Leipsic JA, Mancini GJ, Budoff MJ, Hague CJ, Min JK, O'Brien SM, Hochman JS, **Maron DJ¹**, Reynolds HR; ISCHEMIA Research Group. Stress Echocardiography in Patients with Moderate or Severe Myocardial Ischemia: Insights from the ISCHEMIA Trial. J Am Soc Echocardiogr. 2025 Mar 18:S0894-7317(25)00150-6. doi: 10.1016/j.echo.2025.03.006. Epub ahead of print. PMID: 40112959.

159. **Maron DJ**, Newman JD, Anthopolos R, Lu Y, Stevens S, Boden WE, Mavromatis K, Linefsky J, Nair RG, Bockeria O, Gosselin G, Perna GP, Demchenko E, Foo D, Shapiro MD, Champagne MA, Ballantyne C, McCullough P, Lopez-Sendon JL, Rockhold F, Harrell F, Rosenberg Y, Stone GW, Bangalore S, Reynolds HR, Spertus JA, Hochman JS; ISCHEMIA Research Group. Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial. *J Am Coll Cardiol*. 2025 Apr 1;85(12):1317-1331. doi: 10.1016/j.jacc.2025.01.028. PMID: 40139888.
160. Bangalore S, Mancini GBJ, Leipsic J, Budoff MJ, Xu Y, Anthopolos R, Brilakis ES, Dwivedi A, Spertus JA, Jones PG, Cho YJ, Mark DB, Hague CJ, Min JK, Reynolds HR, Elghamaz A, Nair RG, Mavromatis K, Gosselin G, Banerjee S, Pejkov H, Lindsay S, Grantham JA, Williams DO, Stone GW, O'Brien SM, Hochman JS, **Maron DJ**; ISCHEMIA Research Group. Invasive vs Conservative Management of Patients with Chronic Total Occlusion: Results From the ISCHEMIA Trial. *J Am Coll Cardiol*. 2025 Apr 1;85(12):1335-1349. doi: 10.1016/j.jacc.2025.01.029. PMID: 40139890.
161. Lerner JB, Pleasure M, Min JK, Picard MH, Peteiro J, Senior R, Celutkiene J, Shapiro MD, Pellikka PA, de Quadros AS, Chow BJW, Tamis-Holland JE, Rodriguez F, Fleg JL, **Maron DJ**¹, Hochman JS, Reynolds HR; CIAO-ISCHEMIA Research Group. Quantitative Coronary Artery Plaque Parameters and Severity of Ischemia in Patients With INOCA. *Circ Cardiovasc Imaging*. 2025 Mar 31:e017367. doi: 10.1161/CIRCIMAGING.124.017367. Epub ahead of print. PMID: 40163030.
162. Muller M, Liu R, Shah F, Hu J, Held C, Kullo IJ, McManus B, Wallentin L, Newby LK, Sidhu MS, Bangalore S, Reynolds HR, Hochman JS, **Maron DJ**¹, Ruggles KV, Berger JS, Newman JD. Clonal Hematopoiesis of Indeterminate Potential in Chronic Coronary Disease: A Report From the ISCHEMIA Trials Biorepository. *Circ Genom Precis Med*. 2025 Apr 10:e004921. doi: 10.1161/CIRCGEN.124.004921. Epub ahead of print. PMID: 40207358.
163. Naghavi M, Atlas K, Reeves A, Zhang C, Wasserthal J, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Budoff MJ, Branch AD, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloy S, Fayad Z, McConnell MV, Kakadiaris I, **Maron DJ**^{*}, Narula J, Williams K, Shah PK, Abela G, Vliegenthart R, Levy D, Wong ND. AI-enabled opportunistic measurement of liver steatosis in coronary artery calcium scans predicts cardiovascular events and all-cause mortality: an AI-CVD study within the Multi-Ethnic Study of Atherosclerosis (MESA). *BMJ Open Diabetes Res Care*. 2025 Apr 12;13(2):e004760. doi: 10.1136/bmjdr-2024-004760. PMID: 40221147; PMCID: PMC11997824. **Participated in critical revision of the manuscript for important intellectual content.*
164. Bouladian SG, Ngo S, Mastrodicasa D, Eng D, Khandwala N, Sousa D, Chaudhari AS, **Maron DJ**^{*}, Rodriguez F, Sandhu AT. Statin Therapy Persistence Following Opportunistic Screening for Coronary Artery Calcium on Nongated Chest CTs: NOTIFY-EXTEND. *JACC Cardiovasc Imaging*. 2025 Apr 30:S1936-878X(25)00168-8. doi:10.1016/j.jcmg.2025.03.007. Epub ahead of print. PMID: 40372339. **Conceived of study, responsible for funding, and participated in critical revision of the manuscript for important intellectual content.*
165. White HD, O'Brien SM, Boden WE, Fremes SE, Bangalore S, Reynolds HR, Stone GW, Ali ZA, Parakh N, Lopez-Sendon JL, Wang Y, Chen YQ, Mark DB, Chaitman BR, Spertus JA, **Maron DJ**¹, Hochman JS; ISCHEMIA Research Group. Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention and Associated Outcomes in the ISCHEMIA Trial. *Am Heart J*. 2025 May 20:S0002-

- 8703(25)00165-6. doi: 10.1016/j.ahj.2025.05.009. Epub ahead of print. PMID: 40404111.
166. Nurmohamed NS, Ngo-Metzger Q, Taub PR, Ray KK, Figtree GA, Bonaca MP, Hsia JA, Angadageri S, Earls JP, Rodriguez F, Sandhu AT, Min JK, Hoffmann U, **Maron DJ**, Bhatt DL. First myocardial infarction: risk factors, symptoms, and medical therapy. *Eur Heart J*. 2025 Jul 3;ehaf390. doi: 10.1093/eurheartj/ehaf390. Epub ahead of print. PMID: 40605456. *Participated in critical revision of the manuscript for important intellectual content.*
 167. Shaw LJ, Phillips LM, Leipsic J, Broderick S, Mieres JH, Marwick TH, Friedrich MG, Miller T, Lopes RD, Chow B, Cerci R, Blankstein R, DiCarli M, **Maron DJ**¹, Hochman JS, Alexander KP, Stone GW, O'Brien S, Chaitman BR, Kwong RY, Picard MH, Berman DS, Reynolds HR; ISCHEMIA Research Group. Comparative Prognosis by Stress ECG and Stress Imaging: Results From the ISCHEMIA Trial. *JACC Cardiovasc Imaging*. 2025 Jun 26:S1936-878X(25)00263-3. doi: 10.1016/j.jcmg.2025.03.016. Epub ahead of print. PMID: 40637654; PMCID: PMC12252255.
 168. Chandra J, Short S, Rodriguez F, **Maron DJ**, Pagidipati N, Hernandez AF, Mahaffey KW, Shah SH, Kiel DP, Lu MT, Raghu VK; Project Baseline Health Study Group. Deep Learning Chest X-Ray Age, Epigenetic Aging Clocks and Associations with Age-Related Subclinical Disease in the Project Baseline Health Study. *J Gerontol A Biol Sci Med Sci*. 2025 Aug 8:glaf173. doi: 10.1093/gerona/glaf173. Epub ahead of print. PMID: 40795299. *Participated in critical revision of the manuscript for important intellectual content.*
 169. Huded CP, Spertus JA, Jones PG, O'Brien SM, Mark DB, Bangalore S, Stone GW, Williams DO, White HD, Boden WE, Reynolds HR, Hochman JS, **Maron DJ**; ISCHEMIA Research Group. Health Status Outcomes with Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA. *Circulation*. 2025 Sep 5. doi: 10.1161/CIRCULATIONAHA.125.073591. Epub ahead of print. PMID: 40910165.
 170. Ikemura N, Jones PG, Fu Z, Chan PS, Sherrod CF 4th, Arnold SV, Cohen DJ, Mark DB, **Maron DJ**¹, Hochman JS, Spertus JA; ISCHEMIA Research Group. Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease. *J Am Coll Cardiol*. 2025 Sep 16;86(11):782-793. doi: 10.1016/j.jacc.2025.06.044. PMID: 40930615.
 171. Parameswaran V, Bernard J, Bernard A, Deo N, Tsung S, Lyytinen K, Sharp C, Rodriguez F, **Maron DJ**, Dash R. Evaluating Large Language Models and Retrieval-Augmented Generation Enhancement for Delivering Guideline-Adherent Nutrition Information for Cardiovascular Disease Prevention: Cross-Sectional Study. *J Med Internet Res*. 2025 Oct 7;27:e78625. doi: 10.2196/78625. PMID: 41057043. *Participated in critical revision of the manuscript for important intellectual content.*
 172. King SJ, Furst A, Fan J, Chen TP, **Maron DJ**, Heidenreich P, Nallamshetty S, Kalwani NM, Ward JH, Lozama A, Rodriguez F, Sandhu AT. Comparison of the Pooled Cohort and the PREVENT Cardiovascular Disease Risk Equations in the Veterans Health Administration. *Circulation*. 2025 Oct 21;152(16):1183-1185. doi: 10.1161/CIRCULATIONAHA.125.074224. Epub 2025 Oct 20. PMID: 41115165. *Participated in critical revision of the manuscript for important intellectual content.*
 173. Naghavi M, Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Mozafarybazargany M, Hashemi A, Atlas T, Henschke CI, Yankelevitz DF, Mechanick JI, Branch AD, Fried SK, Nasir K, Fayad ZA, McConnell MV, Vliegenthart R, **Maron DJ**, Narula J, Williams KA Sr, Shah PK, Budoff MJ, Levy D,

- Benjamin EJ, Kloner RA, Wong ND. Opportunistic AI-derived adiposity measures from coronary artery calcium scans predict new-onset type 2 diabetes in adults without obesity or hyperglycemia: insights from the AI-CVD study within MESA. *Diabetol Metab Syndr*. 2025 Nov 6;17(1):419. doi: 10.1186/s13098-025-01970-8. PMID: 41199381; PMCID: PMC12590910. *Participated in critical revision of the manuscript for important intellectual content.*
174. Dudum R, Jain SS, Mastrodicasa D, Furst A, Xu S, Ngo S, Eng D, Khandwala N, Sousa D, Chaudhari A, Langlotz C, Sandhu AT, **Maron DJ**,* Rodriguez F. Effects of Real-Time Notification of AI-Detected Incidental Coronary Artery Calcium on Statin Prescription: the NOTIFY-PICTURE Trial. *Circulation*. 2025 Nov 10. doi: 10.1161/CIRCULATIONAHA.125.078155. Epub ahead of print. PMID: 41213130. **Co-senior author on this publication.*
175. Kwong RY, Heydari B, Abbasi S, Mongeon FP, Marcotte F, Friedrich M, Shaw LJ, Xu Y, Anthopoulos R, Bekeredjian R, Monti L, Selvanayagam J, Lesiak M, Picard MH, Berman DS, Bangalore S, Spertus JA, Stone GW, Boden WE, Min J, Mancini GBJ, Leipsic J, Budoff M, Hague C, Hochman JS, **Maron DJ**¹, Reynolds HR; ISCHEMIA Research Group. Stress Cardiac Magnetic Resonance Ischemia Burden and Cardiovascular Events: Post-Hoc Analysis From the ISCHEMIA Trial. *JACC Cardiovasc Imaging*. 2025 Dec 5:S1936-878X(25)00597-2. doi: 10.1016/j.jcmg.2025.10.015. Epub ahead of print. PMID: 41351610.
176. Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Fan W, Mechanick JI, Branch AD, Nasir K, Fayad Z, McConnell MV, Rana JS, Vliegenthart R, **Maron DJ**, Narula J, Budoff MJ, Levy D, Mehran R, Williams KA, Shah PK, Mechanic O, Agatston AS, Kloner RA, Wong ND, Naghavi M. AI-CVD-AF: A Novel Atrial Fibrillation Prediction Model Based on Coronary Artery Calcium Scans. *Eur Heart J Cardiovasc Imaging*. 2026 Jan 27;jeag027. doi: 10.1093/ehjci/jeag027. Epub ahead of print. PMID: 41591983. *Participated in critical revision of the manuscript for important intellectual content.*
177. Naghavi M, Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Mechanick JI, Branch AD, Yip R, Roy SK, Nasir K, Fayad Z, McConnell MV, Kakadiaris IA, Rana JS, Vliegenthart R, **Maron DJ**, Narula J, Williams K Sr, Shah PK, Budoff MJ, Levy D, Mehran R, Kloner RA, Wong ND. AI-derived left-to-right cardiac chamber volume ratios in coronary artery calcium scans strongly predict heart failure. *Eur Heart J Cardiovasc Imaging*. 2026 Mar 27;27(4):791-802. doi: 10.1093/ehjci/jeag027. PMID: 41591983; PMCID: PMC13021276. *Participated in critical revision of the manuscript for important intellectual content.*
178. Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, de-Torres JP, Seijo LM, Mechanick JI, Branch A, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloy S, Fayad ZA, McConnell MV, Kakadiaris IA, Abela GS, Vliegenthart R, **Maron DJ**, Narula J, Williams KA, Shah PK, Budoff MJ, Levy D, Benjamin EJ, Mehran R, Kloner RA, Wong ND, Naghavi M. Artificial Intelligence-derived Measurements of Myosteatoses from Coronary Artery Calcium CT Scans to Predict COPD: The Multi-Ethnic Study of Atherosclerosis. *Radiol Cardiothorac Imaging*. 2026 Feb;8(1):e250205. doi: 10.1148/ryct.250205. PMID: 41609478. *Participated in critical revision of the manuscript for important intellectual content.*
179. Ben Zekry S, Tzimas G, Leipsic J, Broderick S, Mancini GBJ, Hague CJ, Budoff MJ, Min JK, Chaitman BR, Rockhold FW, Cyr D, Shaw LJ, Berman DS, Picard MH,

- Mark DB, Fleg JL, Poh KK, Ali ZA, Stone GW, O'Brien SM, Hochman JS, **Maron DJ**¹, Reynolds HR. Additive Prognostic Value of Functional Performance to Coronary Artery Anatomy: The ISCHEMIA Trial. *Eur Heart J Cardiovasc Imaging*. 2026 Feb 4;jeag032. doi: 10.1093/ehjci/jeag032. Epub ahead of print. PMID: 41639975.
180. Esquenazi-Karonika S, Hochman JS, Lyo J, Xavier M, O'Brien SM, Boumakis S, Naumova A, Mathews PD, Fleg JL, **Maron DJ**. A point-based system to determine authorship eligibility in a large clinical trial: Insights from the ISCHEMIA trial's authorship nomination system. *J Clin Transl Sci*. 2025 Dec 26;10(1):e7. doi: 10.1017/cts.2025.10214. PMID: 41694063; PMCID: PMC12895453.
 181. Parsa S, Shah P, Furst A, Dudum R, Din N, **Maron D**, Heidenreich P, Ward JH, Lozama A, Sandhu AT, Rodriguez F. Association Between Lipoprotein(a) Testing, Lipid-Lowering Therapy Intensification, and Low-Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System. *J Am Heart Assoc*. 2026 Mar 18:e046519. doi: 10.1161/JAHA.125.046519. Epub ahead of print. PMID: 41848055. *Participated in critical revision of the manuscript for important intellectual content.*
 182. Rogers C, **Maron DJ**, Young KM, Kovach J, Farquhar J, Boone JL. Coronary Atherosclerosis in Former NFL Players: A Case Series From the GAMEFILM Registry. *JACC Case Rep*. 2026 Mar 25;31(12):107021. doi: 10.1016/j.jaccas.2026.107021. PMID: 41906582; PMCID: PMC13045565. *Participated in critical revision of the manuscript for important intellectual content.*
 183. Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Mozafarybazargany M, Hashemi A, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Branch AD, Roy SK, Nasir K, Molloy S, Rana JS, Fayad ZA, McConnell MV, Abela GS, Vliegenthart R, **Maron DJ**, Narula J, Williams KA Sr, Shah PK, Budoff MJ, Benjamin EJ, Mehran R, Kloner RA, Wong ND, Naghavi M. AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke. *Stroke*. 2026 Apr 8. doi: 10.1161/STROKEAHA.125.053401. Epub ahead of print. PMID: 41948813. *Participated in critical revision of the manuscript for important intellectual content.*
 184. Grodzinsky A, Cho YJ, Jones PG, Shaw L, Merz CNB, Boden W, Stone G, Mark DB, Spertus JA, **Maron DJ**¹, Hochman JS, Reynolds HR. Sex Differences in Coronary Disease Health Status Outcomes: the ISCHEMIA Trial. *Eur Heart J Qual Care Clin Outcomes*. 2026 Apr 13:qcag052. doi: 10.1093/ehjqcco/qcag052. Epub ahead of print. PMID: 41978343; PMCID: PMC13082453.
 185. Sandhu AT, Furst A, Rodriguez F, Kalwani N, **Maron D**, Nallamshetty S, Din N, Zitko K, Khachatourian K, Skaar JR, Tonnu-Mihara I. Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease. *JACC Adv*. 2026 Apr 22;5(5):102765. doi: 10.1016/j.jacadv.2026.102765. Epub ahead of print. PMID: 42025258. *Participated in critical revision of the manuscript for important intellectual content.*
 186. Singh A, Brown DL, Jones PG, Fu Z, Reynolds HR, Boden WE, O'Brien SM, Mavromatis K, Poh KK, Ali Z, Stone GW, Bangalore S, Spertus JA, **Maron DJ**¹, Hochman JS; ISCHEMIA Research Group. Residual Angina Following Complete Revascularization in the ISCHEMIA Trial: Frequency, Clinical Characteristics, Health Status, and Cardiovascular Outcomes. *J Am Heart Assoc*. 2026 May 14:e047355. doi: 10.1161/JAHA.125.047355. Epub ahead of print. PMID: 42132177.
 187. Fahed G, Gjermeni D, Cauwenberghs N, Santana EJ, Celestin BE, Bagherzadeh SP, Alexander KM, Salerno M, Kusnetsova T, Shah SH, Daubert MA, Rodriguez F,

- Maron DJ**, Douglas PS, Mahaffey KW, Haddad F. Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: *Insights From the Project Baseline Health Study*. J Am Heart Assoc. 2026 May 29:e045753. doi: 10.1161/JAHA.125.045753. Epub ahead of print. PMID: 42216265. *Participated in critical revision of the manuscript for important intellectual content.*
188. Sandhu AT, Furst A, Rodriguez F, Kalwani N, **Maron DJ**, Nallamshetty S, Din N, Fan M, Khachatourian K, Skaar JR, Tonnu-Mihara I. Trends in post-discharge major adverse cardiovascular events following myocardial infarction: Insights from the veterans healthcare administration. Am J Prev Cardiol. 2026 Apr 9;27:101626. doi: 10.1016/j.ajpc.2026.101626. PMID: 42291033; PMCID: PMC13261270. *Participated in critical revision of the manuscript for important intellectual content.*
189. Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Fan W, Mechanick JI, Branch AD, Fayad Z, McConnell MV, Rana JS, Vliegenthart R, **Maron DJ**, Narula J, Budoff MJ, Mehran R, Williams KA Sr, Shah PK, Mechanic O, Agatston AS, Kloner RA, Wong ND, Naghavi M. AI-CVD-HF: A heart failure risk prediction model based on coronary artery calcium scans compared with PREVENT-HF. Am J Prev Cardiol. 2026 Feb 10;27:101464. doi: 10.1016/j.ajpc.2026.101464. PMID: 42291061; PMCID: PMC13261169. *Participated in critical revision of the manuscript for important intellectual content.*
190. Muller M, Cornwell MG, Rajkumar S, Chen Z, Coit D, Drouard G, Sastourne-Haletou P, Yang H, Raitakari O, Lehtimäki T, Hochman J, **Maron DJ**¹, Berger JS, Newman JD, Ruggles KV; ISCHEMIA Biorepository Research Group. Whole blood epigenomic and transcriptomic characterization identifies vulnerable molecular subtypes of chronic coronary disease. Nat Commun. 2026 Jun 16. doi: 10.1038/s41467-026-73815-5. Epub ahead of print. PMID: 42303606.

¹*As Co-Chair of the ISCHEMIA trial, I was deeply involved in obtaining funding. As Chair of the Publications Committee, I reviewed and approved the manuscript proposal and analysis plan (conception and design) and participated extensively in analysis, interpretation of data, and critical revision of the manuscript for important intellectual content.*

²*As Co-Chair of the ISCHEMIA-CKD trial, I was deeply involved in obtaining funding. As Chair of the Publications Committee, I reviewed and approved the manuscript proposal and analysis plan (conception and design) and participated extensively in analysis, interpretation of data, and critical revision of the manuscript for important intellectual content.*

[B. Peer-reviewed Reviews, Editorials, Clinical Practice Statements, Appropriate Use Criteria, Letters to the Editor](#)

191. **Maron DJ**. Preventive medicine in practice: The state of the art (from a medical student). *West J Med* 1981;134:367-372.
192. Froelicher VF, **Maron D**. Exercise testing and ancillary techniques to screen for coronary heart disease. *Prog Cardiovasc Dis* 1981;24:261-274.
193. **Maron DJ**. Primary and secondary prevention strategies for coronary artery disease. In: U.S. Medical Costs and Values: Primary Prevention Versus End-Stage Treatment. (monograph) Weir MR, Schroeder JS (eds). Cahners Healthcare Communications, Belle Meade, NJ, 1995; pp. 12-15.

194. **Maron DJ.** Nonlipid primary and secondary prevention strategies for coronary heart disease. *Clin Cardiol* 1996; 19:419-423.
195. **Maron DJ,** Rader D. Current strategies for primary prevention of CAD. *Patient Care* 1998;32:19-38.
196. **Maron DJ,** Fazio S, Linton MF. Current perspectives on statins. *Circulation* 2000;101:207-213.
197. **Maron DJ.** Commentary on "Atorvastatin was at least as effective as PTCA for reducing ischemic events in patients with stable coronary artery disease." *ACP J Club.* Jan/Feb 2000;132:7. Comment on: Pitt B, Waters D, Brown WV, et al., for the Atorvastatin Versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. *N Engl J Med.* 1999 Jul 8;341:70-6.
198. **Maron DJ.** The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. *Am J Cardiol* 2000;86(suppl):11L-14L.
199. **Maron DJ.** Dyslipidemia Update. In: Hurst's The Heart [online at Access Medicine Website]. Fuster V, Alexander RW, O'Rourke R, Roberts R, King SB, Nash IS (eds). McGraw-Hill, Inc., New York, NY, 2002
200. **Maron DJ.** Flavonoids for reduction of atherosclerotic risk. *Curr Atheroscler Rep* 2004;6:73-78.
201. **Maron DJ.** Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels? *Nature Clinical Practice Cardiovascular Medicine* 2004;1:18-19.
202. Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. *Ann Intern Med* 2005;143:593-599.
203. Ali YS, **Maron DJ.** Screening for coronary disease in diabetes: when and how. *Clin Diabetes* 2006;24:169-173.
204. **Maron DJ.** Does late PCI improve clinical outcome and survival in patients with arterial occlusion after MI? *Nature Clinical Practice Cardiovascular Medicine* 2007;4:251.
205. Boden WE, **Maron DJ.** Reducing post-myocardial infarction mortality in the elderly: the power and promise of secondary prevention. *J Am Coll Cardiol* 2008;51:1255-57.
206. **Maron DJ.** Using COURAGE to treat angina. *Medscape J Med.* 2008;10(12):286.
207. Shaw LJ, Veledar E, Berman DS, Hayes SW, Friedman J, Slomka P, Germano G, **Maron DJ,** Mancini GBJ, Hartigan PM, Weintraub WS, O'Rourke RA, Heller GV, Dada M, Spertus JA, McCallister B, Chaitman BR, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Bates ER, Teo KK, Boden WE, for the COURAGE Investigators. Response to letters regarding article, "Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy" *Circulation* 2008;118 e840-e841.
208. Bittl JA, **Maron DJ.** Having it both ways. *J Am Coll Cardiol* 2009;55:865-66.
209. Sedlis SP, Boden WE, Weintraub WS, **Maron DS,** O'Rourke RA, Berman DS, Mancini GB; COURAGE study Investigators. Re: One year perspective on COURAGE. *Catheter Cardiovasc Interv.* 2009 Feb 15;73(3):428. doi: 10.1002/ccd.21848. PMID: 19133682.
210. **Maron DJ.** ACP Journal Club. Review: statins do not reduce mortality in patients with no history of cardiovascular disease. *Ann Intern Med* 2010;153:JC3-4.

211. **Maron DJ**, Boden WE, Weintraub WS, Calfas KJ, O'Rourke RA. Is optimal medical therapy as used in the COURAGE trial feasible for widespread use? *Curr Treat Options Cardiovasc Med* 2011;13:16-25.
212. Dresen WF, Wells QS, **Maron DJ**, McPherson JA. Therapeutic procedures for coronary vasospasm-induced polymorphic ventricular tachycardia. *Ther Adv Cardiovasc Dis* 2012;6:115-21.
213. **Maron DJ**, Ting HH. In mildly symptomatic patients, should an invasive strategy with catheterization and revascularization be routinely undertaken?: in mildly symptomatic patients, an invasive strategy with catheterization and revascularization should not be routinely undertaken. *Circ Cardiovasc Interv* 2013;6:114-21.
214. **Maron DJ**, Hochman JS. Revascularization for silent ischemia?: another piece of the puzzle. *J Am Coll Cardiol* 2013;61:1624-5.
215. Phillips LM, Hachamovitch R, Berman DS, Iskandrian AE, Min JK, Picard MH, Kwong RY, Friedrich M, Scherer-Crosbie M, Hayes SW, Sharir T, Gosselin G, Mazzanti M, Senior R, Beanlands R, Smanio P, Goyal A, Al Mallah M, Reynolds H, Stone G, **Maron DJ**, Shaw LJ. Lessons learned from MPI & physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. *J Nuc Cardiol* 2013;20:969-75.
216. **Maron DJ**, Boden WE. As REGARDS treatment goal attainment compared to COURAGE, the perfect should not be the enemy of the good. *J Am Coll Cardiol* 2014;63:634-5.
217. **Maron DJ**, Hlatky MA. TACT and equipoise: When evidence conflicts with beliefs. *Am Heart J* 2014;168:4-5.
218. Shaw LJ, Berman DS, Stone GW, Picard MH, Friedrich MG, Kwong RY, Senior R, Min JK, Hachamovitch R, Scherrer-Crosbie M, Mieres JH, Marwick TH, Phillips LM, Chaudhry FA, Pellikka PA, Slomka P, AE, Iskandrian AE, Bateman TM, Heller GV, Miller TD, Nagel E, Abhinav Goyal A, Salvador Borges-Neto S, Boden WE, Reynolds HR, Hochman JS, **Maron DJ**, Douglas PS. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. *JACC Cardiovasc Imaging* 2014;7:593-604.
219. Rodriguez F, **Maron DJ**. A 60-Year-Old Man Presents With Angina During Physical Activity of Moderate Intensity. <http://angina.cardiosource.org>. Retrieved November 19, 2014 from <http://angina.cardiosource.org/Case-Challenge/2014/11/A-60-Year-Old-Man-Presents-With-Chronic-Angina-During-Physical-Activity-of-Moderate-Intensity.aspx>.
220. Rodriguez F, **Maron DJ**. Ivabradine in Stable Coronary Artery Disease: The SIGNIFY Trial. <http://angina.cardiosource.org>. November 19, 2014. Retrieved from <http://angina.cardiosource.org/Article-of-the-Month/2014/11/Ivabradine-in-Stable-CAD-SIGNIFY-Trial.aspx>
221. Doran B, Guo Y, Xu J, Weintraub H, Mora S, **Maron DJ**, Bangalore S. Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". *Circulation* 2015;131:e473.
222. **Maron DJ**, Hunt SA. Primary prevention of heart failure in older adults. *JACC Heart Failure* 2015;3:529-30.
223. **Maron DJ**, Boden WE. Why optimal medical therapy should be a universal standard of care. *J Am Coll Cardiol* 2015;66: 774-6.
224. Bangalore S, **Maron DJ**, Hochman JS. Evidence-Based Management of Stable Ischemic Heart Disease: Challenges and Confusion. *JAMA* 2015;314:1917-18.

225. Hong J, **Maron DJ**, Shirai T, Weyand CM. Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. *Int J Clin Rheumatol* 2015 Oct;10:365-381.
226. Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB, Jr., Harrington RA, **Maron DJ**. Medical therapy with versus without revascularization in stable patients with moderate and severe ischemia: the case for community equipoise. *J Am Coll Cardiol* 2016;67:81-99.
227. Cheng-Torres KA, Desai KP, Sidhu MS, **Maron DJ**, Boden WE. Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial? *Future Cardiol* 2016;12:35-44.
228. Bangalore S, **Maron DJ**, Hochman JS. Treatment of Patients With Stable Ischemic Heart Disease—Reply. *JAMA* 2016;315:1905-1906.
229. Narayan SM, Baykaner T, **Maron DJ**. Can cardiac conduction system disease be prevented? *JAMA Intern Med* 2016;176:1093-4.
230. **Maron DJ**, Sandhu AT. Using Commercial Programs for Lifestyle Intervention: Not Reinventing the Wheel. *J Am Coll Cardiol* 2017;70:328-330.
231. Rodriguez F, **Maron DJ**, Heidenreich PA. Intensity of Statin Treatment and Mortality-Reply. *JAMA Cardiol* 2017;2:928-929.
232. Bittl JA, **Maron DJ**. Using Absolute Event Rates to See What Works in Cardiovascular Medicine. *J Am Coll Cardiol* 2017;70:1376-1378.
233. **Maron DJ**. Preventive Interventions After Coronary Artery Calcium Scanning: Seeing is Believing. *JACC Cardiovasc Imaging* 2017;10:843-844.
234. Hochman JS, **Maron DJ**. Letter by Hochman and Maron Regarding Article, "'Faith Healing' and 'Subtraction Anxiety' in Unblinded Trials of Procedures: Lessons From DEFER and FAME-2 for End Points in the ISCHEMIA Trial." *Circ Cardiovasc Qual Outcomes* 2018 Apr;11(4):e004742. doi: 10.1161/CIRCOUTCOMES.118.004742.
235. Leonard D, Shah NS, Barlow CE, DeFina LF, Willis BL, **Maron DJ**. The Reply. *Am J Med* 2018 May;131(5):e211. doi: 10.1016/j.amjmed.2017.11.018.
236. Patel MR, Calhoun JH, Dehmer GJ, Grantham JA, Maddox TM, **Maron DJ**, Smith PK. Correction to: ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease. *J Nucl Cardiol* 2018 May 10. doi: 10.1007/s12350-018-1292-x. [Epub ahead of print]
237. Bangalore S, **Maron DJ**, Reynolds HR, Stone GW, O'Brien SM, PhD; Alexander KP, Hochman JS. ISCHEMIA: Establishing the Primary Endpoint. *Circ Cardiovasc Qual Outcomes* 2018;11:e004791. DOI: 10.1161/CIRCOUTCOMES.118.004791.
238. **Maron DJ**, Harrington RA, Hochman JS. Planning and Conducting the ISCHEMIA Trial: Setting the Record Straight. *Circulation* 2018;138:1384–1386.
239. Sandhu AT, **Maron DJ**. Coronary CT Angiography and Subsequent Risk of Myocardial Infarction. *N Engl J Med* 2019 Jan 17;380(3):299. doi: 10.1056/NEJMc1816189.
240. Naghavi M, **Maron DJ**, Kloner RA, Berman DS, Budoff M, Superko HR, Shah PK. Coronary artery calcium testing: A call for universal coverage. *Prev Med Rep*. 2019 May 2;15:100879. doi: 10.1016/j.pmedr.2019.100879. eCollection 2019 Sep. Review.
241. Rodriguez F, **Maron DJ**, Heidenreich PA. Studies evaluating statin adherence and outcome should adjust for smoking persistence and antiplatelet treatment discontinuation-Reply. *JAMA Cardiol*. 2019 Jun 26. doi:10.1001/jamacardio.2019.1969. [Epub ahead of print]
242. Shapiro MD, **Maron DJ**, Morris PB, Kosiborod M, Sandesara PB, Virani SS, Khera A, Ballantyne CM, Baum SJ, Sperling LS, Bhatt DL, Fazio S. Preventive cardiology

- as a subspecialty of cardiovascular medicine: JACC Council Perspectives. *J Am Coll Cardiol*. 2019;74:1926-1942.
243. Sarraju A, Rodriguez F, **Maron DJ**. Practical Implications of the ISCHEMIA Trial. <http://www.acc.org>. May 14, 2020. Accessed 5.14.20. <https://www.acc.org/latest-in-cardiology/articles/2020/05/14/13/12/practical-implications-of-the-ischemia-trial>.
 244. Maron DJ, Hochman JS. Invasive or Conservative Strategy for Stable Coronary Disease. Reply. *N Engl J Med*. 2020 Sep 3;383(10):e66. doi: 10.1056/NEJMc2024008. PubMed PMID: 32877596.
 245. Bangalore S, **Maron DJ**, Hochman JS. Management of Coronary Disease in Patients with Advanced Kidney Disease. Reply. *N Engl J Med*. 2020 Sep 10;383(11):1091-1092. doi: 10.1056/NEJMc2024023. PMID: 32905690
 246. Greenland P, Michos ED, Redmond N, Fine LJ, Alexander KP, Ambrosius WT, Bibbins-Domingo K, Blaha MJ, Blankstein R, Fortmann SP, Khera A, Lloyd-Jones DM, **Maron DJ**, Min JK, Muhlestein JB, Nasir K, Sterling MR, Thanassoulis G. Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop. *JACC Cardiovasc Imaging*. 2020 Sep 11:S1936-878X(20)30650-1. doi: 10.1016/j.jcmg.2020.06.042. Online ahead of print. PMID: 32950442.
 247. Bryant, E., Janaszek, K., Nejedly, M., Li, E., Bouvier, M., Schroeder, K., Khandelwal, A., Lough, M. E., Lamendola, C., Reisenberg, A., Purewal, S., **Maron, D. J.** Nurse Practitioner-Directed Cardio-Diabetes Pilot Program. *Journal for Nurse Practitioners* 2020;16: E123–E128.
 248. Wongvibulsin S, Habeos EE, Huynh PP, Xun H, Shan R, Porosnicu Rodriguez KA, Wang J, Gandapur YK, Osuji N, Shah LM, Spaulding EM, Hung G, Knowles K, Yang WE, Marvel FA, Levin E, **Maron DJ**, Gordon NF, Martin SS. Digital Health Interventions for Cardiac Rehabilitation: Systematic Literature Review. *J Med Internet Res*. 2021;23:e18773. doi: 10.2196/18773.
 249. Bangalore S, **Maron DJ**, Stone GW, Hochman JS. Response by Bangalore et al to Letter Regarding Article, "Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials." *Circulation*. 2021 Apr 6;143(14):e809-e810.
 250. Ali ZA, Horst J, Gaba P, Shaw LJ, Bangalore S, Hochman JS, **Maron DJ**, Moses JW, Alfonso MA, Madhavan MV, Dressler O, Reynolds H, Stone GW. Standardizing the Definition and Analysis Methodology for Complete Coronary Artery Revascularization. *J Am Heart Assoc*. 2021 May 4;10(9):e020110.
 251. Lopes RD, Alexander KP, Hochman JS, **Maron DJ**. Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial." *Circulation*. 2021;143:e961-e962.
 252. Chaitman BR, Reynolds HR, **Maron DJ**, Hochman JS. Response by Chaitman et al to Letter Regarding Article, "Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons." *Circulation*. 2021 Jul 13;144(2):e14-e15. doi: 10.1161/CIRCULATIONAHA.121.055296. Epub 2021 Jul 12.
 253. **Maron DJ**, Bangalore S, Hochman JS. The Glass Is at Least Half Full. *JACC Cardiovasc Interv*. 2021;14:2350-2352.
 254. Heidenreich PA, Clarke SL, **Maron DJ**. Time to Relax the 40-Year Age Threshold for Pharmacologic Cholesterol Lowering. *J Am Coll Cardiol*. 2021;78:1965–1967.

255. Budoff MJ, Lakshmanan S, Toth PP, Hecht HS, Shaw LJ, **Maron DJ**, Michos ED, Williams KA, Nasir K, Choi AD, Chinnaiyan K, Min J, Blaha M. Cardiac CT angiography in current practice: An American Society for Preventive Cardiology Clinical Practice Statement. *Am J Prev Cardiol.* 2022;9:100318.
256. **Maron DJ**. A commentary on: CT or Invasive Coronary Angiography in Stable Chest Pain. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/ct-or-invasive-coronary-angiography-in-stable-chest-pain/132807/65/2/1>. Accessed March 16, 2022
257. **Maron DJ**, Bangalore S, Reynolds, HR, Hochman JS. Letter to the Editor. Revascularization and Survival in Multivessel Coronary Artery Disease in ISCHEMIA. *JTCVS Open.* 2022 Apr 14;10:243. doi: 10.1016/j.xjon.2022.03.006. eCollection 2022 Jun. PMID: 36004229
258. Bangalore S, Hochman JS, Stevens SR, Jones PG, Spertus JA, O'Brien SM, Reynolds HR, Boden WE, Fleg JL, Williams DO, Stone GW, Sidhu MS, Mathew RO, Chertow GM, **Maron DJ**. Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. *JAMA Cardiol.* 2022 Jun 29. doi: 10.1001/jamacardio.2022.1763. Online ahead of print. PMID: 35767253
259. Greenland P, **Maron DJ**, Budoff MJ. Insurance Payers Should Cover Selective Coronary Artery Calcium Testing in Intermediate Risk Primary Prevention Patients *Circulation.* 2022 Aug 23;146(8):585-586. doi: 10.1161/CIRCULATIONAHA.122.061193.
260. Cardoso R, Leslee J, Shaw LJ, Blumenthal RS, Nasir K, Ferraro R, **Maron DJ**, Blaha MJ, Gulati M, Bhatt DL, Blankstein R. Preventive cardiology advances in the 2021 AHA/ACC chest pain guideline. *Am J Prev Cardiol.* 2022 Jun 30;11:100365. doi: 10.1016/j.ajpc.2022.100365. eCollection 2022 Sep. PMID: 35844247
261. Mavromatis K, Boden WE, **Maron DJ**, Mancini GBJ, Weintraub WS, Gosselin G, Berman DS, Shaw LJ, Spertus JA, Hochman JS. Comparison of Outcomes of Invasive or Conservative Management of Chronic Coronary Disease in Four Randomized Controlled Trials. *Am J Cardiol.* 2022 Dec 15;185:18-28. doi: 10.1016/j.amjcard.2022.09.008. Epub 2022 Oct 17. PMID: 36257844.
262. Freeman AM, Raman SV, Aggarwal M, **Maron DJ**, Bhatt DL, Parwani P, Osborne J, Earls JP, Min JK, Bax JJ, Shapiro MD. Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making. *Am J Med.* 2022 Dec 10:S0002-9343(22)00874-9. doi: 10.1016/j.amjmed.2022.10.021. Epub ahead of print. PMID: 36509122.
263. Baugh CW, Freund Y, Steg PG, Body R, **Maron DJ**, Yiadom MYMAB. Strategies to Mitigate Emergency Department Crowding and Its Impact on Cardiovascular Patients. *Eur Heart J Acute Cardiovasc Care.* 2023 May 10:zuad049. doi: 10.1093/ehjacc/zuad049. Epub ahead of print. PMID: 37163667.
264. Multimodality Writing Group for Chronic Coronary Disease; Winchester DE, **Maron DJ**, Blankstein R, Chang IC, Kirtane AJ, Kwong RY, Pellikka PA, Prutkin JM, Russell R, Sandhu AT. ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease. *J Am Coll Cardiol.* 2023 May 19:S0735-1097(23)05223-3. doi: 10.1016/j.jacc.2023.03.410. Epub ahead of print. PMID: 37245131.
265. Sandhu AT, Rodriguez F, **Maron DJ**. Response by Sandhu et al to Letter Regarding Article, "Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1

- Project)". *Circulation*. 2023 Aug;148(5):441. doi: 10.1161/CIRCULATIONAHA.123.065360. Epub 2023 Jul 31. PMID: 37523759.
266. Winchester DE, **Maron DJ**, Blankstein R, Chang IC, Kirtane AJ, Kwong RY, Pellikka PA, Prutkin JM, Russell R, Sandhu AT. ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease. *J Cardiovasc Magn Reson*. 2023 Oct 19;25(1):58. doi: 10.1186/s12968-023-00958-5. PMID: 37858155; PMCID: PMC10585920.
 267. Stone GW, Ali ZA, Hochman JS, **Maron DJ**. REPLY: Interpreting the Impact of Complete Revascularization in the ISCHEMIA Trial. *J Am Coll Cardiol*. 2024 Jan 30;83(4):e39-e40. doi: 10.1016/j.jacc.2023.11.018. PMID: 38267120.
 268. **Maron DJ**. A commentary on: Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/atherosclerosis-quantification-and-cardiovascular-risk/168933/65/2/1>. Accessed August 18, 2024
 269. **Maron DJ**, Rodriguez F. Seeing is Knowing: Noninvasive Imaging Outperforms Traditional Risk Assessment. *J Am Coll Cardiol*. 2024 Oct 8;84(15):1404-1406. doi: 10.1016/j.jacc.2024.06.048. PMID: 39357938.
 270. **Maron DJ**, Budoff MJ, Sky JC, Bommer WJ, Epstein SD, Fisher DA, Stock EO, Taylor AJ, Wong ND, DeMaria AN. Coronary Artery Calcium Staging to Guide Preventive Interventions: A Proposal and Call to Action. *JACC Adv*. 2024 Sep 24;3(11):101287. doi: 10.1016/j.jacadv.2024.101287. PMID: 39385944; PMCID: PMC11462328.
 271. Kotanidis CP, **Maron DJ**, Jernberg T. Beta-Blocker Therapy after Acute Myocardial Infarction - To Block or Not to Block? *N Engl J Med*. 2025 Mar 27;392(12):1234-1236. doi: 10.1056/NEJMcide2410735. PMID: 40138559.
 272. Naghavi M, Wong ND, McConnell MV, **Maron DJ**, Nasir K, Henschke CI, Yankelevitz DF, A Fayad Z, Vliegenthart R, Williams KA Sr, Mehran R, Budoff M, Berman D, Rana JS, Shah PK, Kloner RA, Narula J, Greenland P, Fuster V. Coronary Artery Calcium (CAC) Imaging as a Diagnostic Test: Insurance Coverage Implications. *JACC Cardiovasc Imaging*. 2025 Dec 9:S1936-878X(25)00631-X. doi: 10.1016/j.jcmg.2025.10.020. Epub ahead of print. PMID: 41379038.
 273. Filtz A, Shapiro MD, Whelton PK, Navar AM, Rodriguez F, Martin SS, Gulati M, Blankstein R, Ridker PM, Bhatt DL, Yancy CW, **Maron DJ**, Slipeczuk L. Evolving strategies in cardiovascular disease prevention: 2025 American society for preventive cardiology highlights. *Am J Prev Cardiol*. 2025 Nov 22;24:101357. doi: 10.1016/j.ajpc.2025.101357. PMID: 41404186; PMCID: PMC12704089.
 274. Bola H, Rai A, Penumaka R, Ulucay E, Levin E, **Maron D**. Cardiac Rehabilitation for Coronary Artery Disease: Gaps, Digital Models, and the Future of Personalized Prevention. *Am J Cardiol*. 2026 Mar 1;262:16-27. doi: 10.1016/j.amjcard.2025.12.013. Epub 2025 Dec 28. PMID: 41468986.
 275. O'Brien SM, **Maron DJ**, Hochman JS. Questions Regarding the ISCHEMIA-PREDICT Mortality Risk Score. *Eur J Prev Cardiol*. 2026 May 24:zwag284. doi: 10.1093/eurjpc/zwag284. Epub ahead of print. PMID: 42177041.

C. [Not Peer-Reviewed Publications](#)

1. **Maron D**. Niacin: vitamin or drug? *Healthline* 1990; 9:8-9.
2. **Maron DJ**. Dyslipidemia. In: EBM Solutions Guidelines for Health Care Providers and Consumers [online database]. Issue 1. Nashville, Tenn: EBM Solutions; 2000.

3. **Maron DJ.** Percutaneous coronary intervention versus medical therapy for coronary heart disease. *Curr Atheroscler Rep* 2000; 2:290-296.
4. Rosenbaum DA, **Maron DJ.** Primary prevention: coronary artery disease. In: EBM Solutions Guidelines for Health Care Providers and Consumers [online database]. Issue 1. Nashville, Tenn: EBM Solutions; 2000.
5. **Maron DJ.** Primary prevention of CAD. In: EBM Solutions Guidelines for Health Care Providers and Consumers [online database]. Issue 1. Nashville, Tenn: EBM Solutions, Inc.; August 2000.
6. Rosenbaum DA, **Maron DJ.** Primary prevention of CAD. In: EBM Solutions Guidelines for Health Care Providers and Consumers [online database]. Issue 2. Nashville, Tenn: EBM Solutions, Inc.; Update 1: April 1, 2001.
7. **Maron DJ.** Primary prevention of CAD. In: EBM Solutions Guidelines for Health Care Providers and Consumers [online database]. Issue 3. Nashville, Tenn: EBM Solutions, Inc.; Update 2: June 14, 2002.

D. Book Chapters

1. Fortmann SP, **Maron DJ.** Diagnosis and Management of Lipid Disorders. In: Scientific American Medicine. Dale DC, Federman DD (eds). Scientific American, Inc., New York, N.Y., 1991-1998.
2. **Maron DJ,** Ridker PM, Pearson TA. Risk Factors and the Prevention of Coronary Heart Disease. In: Hurst's The Heart. Alexander RW, Schlant RC, Fuster V (eds). 9th Edition. McGraw-Hill, Inc., New York, NY, 1998; pp. 1175-1195.
3. **Maron DJ,** Ridker PM, Pearson TA, Grundy SM. Dyslipidemia, Other Risk Factors, and the Prevention of Coronary Heart Disease. In: Hurst's The Heart. Fuster V, Alexander RW, O'Rourke R, Roberts R, King S, Wellens H (eds). 10th Edition. McGraw-Hill, Inc., New York, NY, 2000; pp. 2352-2392.
4. Pearson TA, **Maron DJ,** Ridker PM, Grundy SM. Dyslipidemia and Risk Factors in the Prevention of Coronary Heart Disease. In: Hurst's The Heart Manual of Cardiology. O'Rourke R, Fuster V, Alexander RW, Roberts R, King SB, Wellens H JJ (eds). 10th Edition. McGraw-Hill, Inc., New York, NY, 2001; pp. 221-236.
5. **Maron DJ,** Grundy SM, Ridker PM, Pearson TA. Dyslipidemia, Other Risk Factors, and the Prevention of Coronary Heart Disease. In: Hurst's The Heart. Fuster V, O'Rourke RA, Alexander RW, Roberts R, King S, Nash IS, Prystowsky EN (eds). 11th Edition. McGraw-Hill, Inc., New York, NY, 2004.
6. **Maron DJ,** Grundy SM, Ridker PM, Pearson TA. Dyslipidemia, Other Risk Factors, and the Prevention of Coronary Heart Disease. In: Hurst's The Heart Manual of Cardiology. O'Rourke R, Fuster V, Alexander RW, Roberts R, King S, Nash IS, Prystowsky EN (eds). 11th Edition. McGraw-Hill, Inc., New York, NY, 2005; pp. 195-219.
7. **Maron DJ,** Ridker PM, Grundy SM, Pearson TA. Preventive Strategies for Coronary Heart Disease. Hurst's The Heart. Fuster V, O'Rourke RA, Walsh RA, Poole-Wilson P (eds). 12th Edition. McGraw-Hill, Inc., New York, NY, 2008.
8. Huang R, **Maron DJ.** Preventive Strategies for Coronary Heart Disease. In: Hurst's The Heart Manual of Cardiology. O'Rourke R, Fuster V (eds). 12th Edition. McGraw-Hill, Inc., New York, NY, 2009.
9. Newman J, **Maron DJ.** Secondary Prevention. In: Interventional Cardiology. 2nd Edition. Samady H, Fearon W, Yeung A, King S (eds). McGraw-Hill, Inc., New York, NY, 2017.
10. Sarraju A, **Maron DJ.** Stable Ischemic Heart Disease: Medical Therapy With or Without Revascularization. Scientific American Medicine (online textbook) 2018.

GRANTS/CLINICAL TRIALS

Current Funding

- 10/25-10/27 **HEARTWISE-ASCVD**
Role: Co-Investigator (PIs: Alex Sandhu, Fatima Rodriguez)
Sponsor: Amgen, Inc.
Type: Industry
Goal: To evaluate the clinical effectiveness of a large scale opportunistic coronary artery calcium screening program on change in lipid-lowering therapy and LDL cholesterol among patients with known atherosclerotic cardiovascular disease or CAC >300.
- 9/25 –1/28 **Women’s Health Initiative**
Role: Co-Investigator. (PI: Marcia Stefanick)
Sponsor: National Institutes of Health
Type: N92021D0000
Goal: The Women’s Health Initiative (WHI). Stanford is the Western Regional Center (WRC) of the WHI 2010-2027 Extension, which is continuing to follow participants of the clinical trials (CT: hormone therapy; diet modification; and calcium/vitamin D) and observational study, (OS) (1993-2005), who consented to extended follow-up from 2010 on, with full outcome ascertainment of former HT trial and all African American and Hispanic CT and OS participants and cancer outcomes in all others. The WRC facilitates scientific activities related to cardiovascular disease (with an emphasis on heart failure and atrial fibrillation, as well as CHD, stroke, VTE) and physical activity/body composition.
- 9/24-8/29 **HIDDEN-ASCVD**
Role: Co-Investigator (PIs: Andrew Ambrosy, Alex Sandhu)
Sponsor: Kaiser Permanente (Prime: NHLBI)
Type: R01
Goal: To evaluate the prognostic value of AI-CAC across a real world diverse primary prevention cohort
- 7/24-4/28 **NICE: Novel Incidental Calcium Evaluation**
Role: Co-Investigator (PI: Fatima Rodriguez)
Sponsor: NHLBI
Type: R01
Goal: The objective of NICE is to demonstrate the effectiveness of a deep-learning (DL) algorithm to detect and quantify incidental coronary artery calcium (CAC) from non-gated chest computed tomography (CT) scans and assess the prognostic value of DL-derived CAC (DL-CAC).
- 2/24-2/29 **TRANSFORM**
Role: Study Co-Chair (Chair: Deepak Bhatt)
Sponsor: Cleerly, Inc.
Status of Support: 202302CPC

Goal: This is a randomized, controlled, open-label, multicenter, event-driven pragmatic trial testing the hypothesis that a personalized cardiovascular (CV) care strategy based on atherosclerosis burden reduces CV events compared with a population health strategy based on current American College of Cardiology/American Heart Association guidelines for primary prevention of CV disease (guideline-directed medical therapy [GDMT]).

12/23-11/28 **ADHERES**

Role: Co-Investigator. (PI: Fatima Rodriguez)

Sponsor: National Institutes of Health

Type: R01 HL168188

Adherence Determinants in the Health Electronic Record Evaluation of Statins (ADHERES).

Goal: This study will use an artificial intelligence algorithm to identify patient, clinician, and health system reasons for statin nonuse across diverse patient groups and data sets. This approach could be used to monitor and narrow gaps in statin adherence and increase statin use for millions of high-risk patients.

9/23-5/28 **Opportunistic ASCVD Risk Estimation Using Abdominal CT with Robust and Unbiased Deep Learning**

Role: Co-Investigator (PI: Akshay Chaudhari)

Sponsor: NHLBI

Type: R01

Goal: To develop and validate new tools that use already-acquired abdominal CT scans and pair them with a patient's electronic health records to predict the risk of future cardiovascular disease

7/22-7/24 **Stanford Blood Pressure Trial**

Role: Co-PI. (Co-PI: Steven Lin)

Sponsor: Stanford Health Care and Omada Health, Inc.

Type: Contract SPO251626

Goal: To determine whether Omada Health's remote patient monitoring and health coaching plus usual care is superior to usual care alone in the management of Stanford Primary Care patients with uncontrolled hypertension. The primary outcome will be the difference between treatment groups in mean change in systolic blood pressure after 1 year.

7/22-6/26 **PICTURE**

Role: Co-Investigator. (PI: Fatima Rodriguez)

Sponsor: Doris Duke Charitable Foundation

Type: Grant 2022051

PICTURE (Picture of Incidental Calcium To Understand Risk Estimate)

Goal: The primary objective is to measure the rate of statin initiation after notifying patients and clinicians about the presence of incidental coronary artery calcification found on non-gated chest CT scans.

4/22-3/26 **ISCHEMIA-EXTEND**

Role: Study Co-Chair. (Study Chair: Judith Hochman)

Sponsor: NHLBI
Type: R01HL149888 (20-00-00-1002596)
Goal: The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDED Follow-up (EXTEND). This is long-term follow-up of vital status of participants in the ISCHEMIA and ISCHEMIA-CKD trials (projected median follow-up of 10 years). The overarching objective of long-term follow-up is to assess whether there are between-group differences in long-term all-cause, cardiovascular, and non-cardiovascular mortality. I remain active as Chair of the Publications Committee for numerous secondary publications from ISCHEMIA and ISCHEMIA-CKD.

Pending Funding

- 9/26-8/27 **Reducing the Environmental Footprint of the Restaurant Industry: Empowering Chefs to Embrace Sustainability**
Role: Co-Investigator (PI: Yewon Kim)
Sponsor: Stanford University Doerr School of Sustainability
Type: Intramural grant
Goal: To provide chefs with information about the environmental impact of various ingredients along with their flavor similarities and price levels, recommending a list of alternatives that are both substitutable and compatible under taste and budget constraints.
- 7/26-6/31 **BRIDGE-CKM: Barriers to Real World Implementation of Directed Guideline Based Evidence in Cardiovascular Kidney Metabolic Syndrome**
Role: Co-Investigator (PIs: Fatima Rodriguez, Alex Sandhu)
Sponsor: NIH
Type: R01
Goal: To leverage large language models to identify actionable clinician and patient barriers to use of CKM therapies across several indications from unstructured clinical data.
- 7/26-6/31 **SCREEN-HF: BNP-Based Screening in Primary Care to Prevent Heart Failure in Older Adults**
Role: Co-Investigator (PIs: Alex Sandhu, Andrew Ambrosy)
Sponsor: NIH
Type: R01
Goal: To determine whether a blood test in parentheses B type natriuretic peptide (BNP) used in primary care to identify older adults at elevated risk for HF can reduce hospitalizations and deaths.
- 6/26-5/31 **LIFEMAP: Low-dose Imaging For Early Multi-disease Assessment And Prevention**
Role: Site PI (PI: Bruno De Man)
Sponsor: ARPA-H
Type: Contract
Goal: To develop and test the first autonomous ultra-low-dose CT based screening robot for early detection of multiple diseases.

Past Funding

- 1984-1991 Role: Co-Investigator. Stanford Coronary Risk Intervention Project (SCRIP). Clinical trial to test the efficacy of multiple risk factor intervention on progression of coronary atherosclerosis. Sponsor: NHLBI.
- 1996-1999 Role: Site PI. Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). Funding: Parke-Davis #981-176, Pfizer #258-101
- 1997-2000 Role: Site PI. Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders (WIZARD). Funding: Pfizer #066-192-5026
- 1997-1999 Role: Co-investigator, Effects of Post-Exercise Nutrient Administration on Skeletal Muscle Protein Homeostasis. Principal Investigator: Paul Flakoll, Ph.D. Funding: Pharmavite Corporation, San Fernando, CA
- 1998-2000 Role: Site PI. Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Niaspan® (Extended-Release Niacin Tablets) in Type 2 Diabetic Patients with Dyslipidemia. Funding: Kos Pharmaceuticals #MA-98-0108
- 1998-2000 Role: Co-investigator, The Effect of LDL-Cholesterol Lowering Beyond Currently Recommended Minimum Targets on Coronary Heart Disease Recurrence in Patients with Pre-existing CHD. Principal Investigator: MacRae Linton, M.D. Funding: Parke-Davis #981-117 and Pfizer #258-102.
- 1998-2007 Role: Executive Committee Member and Chairman, Optimal Medical Therapy Committee, COURAGE Trial
Sponsor: Department of Veterans Affairs, Medical Research Council of Canada
Type: Cooperative Studies Program #424
COURAGE Trial. Clinical trial to compare optimal medical therapy with or without percutaneous coronary intervention in the management of stable coronary disease.
- 2000-2003 Role: PI. Cardiovascular Risk Reduction in High Risk Employees. Pilot study on Vanderbilt employees. IRB#990405.
- 2001-2004 Role: Site PI. Advisor in the Treatment of Diabetic Patients with Dyslipidemia Using Thiazolidinedione and/or Metformin (The Anthem Study) Kos protocol MA-01-010402
- 2002-2003 Role: Co-Investigator. Study of Tea Extract on LDL Cholesterol, funded by Nashai Biotech, LLC.
- 2003-2005 Role: Steering Committee member, National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey

This was a national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel guidelines.

- 2007-2011 Co-Investigator. Co-investigator, RO1 HL088459-03, Storrow (PI), NIH/NHLBI study to develop and validate a decision score for ED patients with signs and symptoms of heart failure (STRATIFY).
- 2008-2010 Co-Investigator. 2007.001, Peacock (PI), HeartScape Technologies “Best Expert Agreement for Care of Occult MI Nationally (BEACON)” study to identify which methods facilitate the diagnosis and risk stratification of STEMI or non-STEMI patients.
- 2008-2011 Co-Investigator. Vanderbilt University Central Discovery Grant. PI James Dickerson, Ph.D.; Co-Investigator Todd Giorgio, Ph.D. Noninvasive Detection of Vulnerable Atherosclerotic Plaque Using Multifunctional, Proximity Activated Nanoparticles.
- 2009-2010 Co-Investigator. 087-CL-301, Johnson, McNutt, Wang (PIs), Astellas Pharma, Inc. Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety and Efficacy of “Conivaptan in Symptomatic Acute Decompensated Heart Failure (ADHF) Subjects with Hyponatremia (CONVERT-H)” The study objectives are to evaluate the safety and efficacy of conivaptan in hyponatremic subjects with symptomatic ADHF.
- 2009-2010 Co-Investigator. TMC-CLV-08-01, Peacock (PI), The Medicines Company, A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure – A Pilot Study (PRONTO), Study objective: to evaluate the efficacy and safety of an IV infusion of clevidipine as compared with standard of care IV antihypertensive for blood pressure lowering in patients with acute heart failure and elevated blood pressure.
- 5/11-7/21 Principal Investigator and Study Co-Chair. (Chair: Judith Hochman)
Sponsor: NHLBI
Type: U01 (U01HL105907, U01HL105462, U01HL105561, and U01HL105565)
The ISCHEMIA Trial. ISCHEMIA was designed to determine whether an initial invasive strategy of cardiac catheterization and revascularization plus optimal medical therapy reduces cardiovascular events in patients with at least moderate ischemia as compared with an initial conservative strategy of optimal medical therapy alone, with catheterization reserved for failure of medical therapy. Main results published in NEJM 3/30/20. Active as Chair of the Publications Committee for numerous secondary publications.
- 5/13-12/21 Study Co-Chair. (Sripal Bangalore Principal Investigator).
Sponsor: NHLBI
Type: U01HL117904 and U01HL1179050
ISCHEMIA-CKD Trial ISCHEMIA-CKD was an ancillary trial to ISCHEMIA comparing the effectiveness of an initial invasive strategy

with an initial conservative strategy in the management of patients with stable ischemic heart disease, at least moderate ischemia, and chronic kidney disease. Main results published 3/30/20. Active as Chair of the Publications Committee for numerous secondary publications.

- 4/17-4/21 Co-Investigator. Cardiovascular disease lead at Stanford. (PI Jessica Mega).
Sponsor: Verily
Project Baseline. Longitudinal cohort study to understand the molecular basis of health and transition to disease by collecting serial biomedical data from 2,000 participants over four years.
- 12/18-12/19 Co-Investigator. (PI Dan Azagury)
Type: Seed grant.
Sponsor: Stanford Department of Surgery
BAROS. Bariatric Surgery vs. Catheter Ablation for the Treatment of Atrial Fibrillation. Clinical trial to compare the efficacy of catheter ablation following bariatric surgery vs. catheter ablation alone in the management of atrial fibrillation in patients with morbid obesity.
- 5/19-4/20 Co-Principal Investigator. (Co-PI Bhavik Patel)
Sponsor: Stanford Human-Centered Artificial Intelligence Institute
Type: Seed grant.
Opportunistic Screening for Coronary Artery Disease Using Artificial Intelligence (a pilot study). Clinical trial to test the efficacy of patient and physician notification of the presence of coronary artery calcification on non-gated chest CT scans, detected by an artificial intelligence algorithm, on statin prescription.
- 9/23-9/25 Role: PI.
Sponsor: Genentech, Inc.
Type: GC43343
A phase Ic multicenter, randomized, double-blind, placebo controlled study to assess the safety, pharmacokinetics, and pharmacodynamics following 4 weeks of NLRP3 inhibition with selnoflast in participants with coronary artery disease.

EDITORIAL SERVICE

Editorial Appointments:

- | | |
|--------------|---|
| 2008-2016 | Editor-in-Chief, Medscape Reference Cardiology |
| 2020-present | Editorial Board, American Journal of Preventive Cardiology |
| 2023, 2024 | Guest Editor, Journal of the American College of Cardiology |

Ad Hoc Reviewer:

American Heart Journal
American Journal of Cardiology
Circulation

Circulation Cardiovascular Quality and Outcomes
Clinical Nutrition
European Journal of Nutrition
JAMA
JAMA Cardiology
JAMA Internal Medicine
Journal of the American College of Cardiology
JACC Cardiovascular Imaging
JACC Heart Failure
Lancet
New England Journal of Medicine

Other Peer Review:

ACC/AHA Guideline reviewer appointments

- 2011 PCI guidelines document

- 2013 ACCF/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease

- 2015 Focused Update on Primary PCI for Patients With STEMI: An Update of the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction and the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

- 2015 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease

SERVICE AS GRANT REVIEWER

2011 Dutch Diabetes Research Foundation Application

2022 NIH Study Section (Special Emphasis Panel):

Reviewer for NHLBI and NINDS infrastructure grants for The Strategies to Innovate EmergEncy Care (SIREN) Clinical Trials Network

UNIVERSITY ADMINISTRATIVE SERVICE

Committee service (Vanderbilt University):

1994-1995	Medical Director, Cardiology Clinic, VUMC
1994-1995	Member, Clinical Services Committee
1995	Preventive Medicine Task Force, Committee on Cholesterol, VUMC
2005-2006	Member, Clinical Advisory Committee to Vanderbilt Center for Integrative Health
2007-2013	Member, Chest Pain Center Committee

2010-2013	Member, Pain Program Steering Committee
2011-2013	Member, Cancer Wellness Medical Advisory Council
Committee service (Stanford University):	
2014-present	Interviewer, Internal Medicine Residency applicants
2014-present	Interviewer, Cardiology Fellowship applicants
2015-2016	Faculty search committee member for Cardiovascular Institute/General Medical Disciplines
2016-2017	Task force to develop Emergency Department Chest Pain Algorithm
2018-present	Member, Cardiovascular Medicine Evaluation Unit to review reappointments and promotions within the division
2019	Faculty search committee member for Non-Invasive Imaging Cardiologist
2022	Faculty search committee member for joint appointment to the Stanford Center for Biomedical Informatics Research and the Division of Cardiovascular Medicine in the Department of Medicine.

Leadership roles (Vanderbilt University):

1995-1999, 2001-2013	Medical Director, Dayani Center for Health and Wellness, VUMC
1995-1999, 2001-2013	Medical Director, Vanderbilt Cardiac Rehabilitation Program
1997-2002	Founder and Director, Vanderbilt Heart Disease Prevention Program
1999-2000	Clinical Advisor to WebEBM, Inc. Appointed to this position by Vice Chancellor, Harry Jacobson, M.D. WebEBM combined evidence-based medical knowledge with interactive technology. Along with advisers from four other top 25 academic medical centers, I supervised the development of evidence-based guidelines and integrated them with tools to translate evidence into practice.
2000-2007	Founder and Chief Medical Officer, Cardiovascular Services of America (CSA), Inc. Vanderbilt was a co-founder.
2007-2009	Clinical Advisor, HealthTech Lab
2007-2013	Director, Emergency Cardiology
2007-2013	Director, Vanderbilt Chest Pain Unit

Leadership roles (Stanford University):

2014-present	Director, Preventive Cardiology, Stanford University
2015-2017	Co-Director, General Cardiology Inpatient Service
2015-2016	Department of Medicine Faculty Mentor Program
2017-2019	Interim Chief, Stanford Prevention Research Center
2019-present	Chief, Stanford Prevention Research Center

SERVICE TO PROFESSIONAL ORGANIZATIONSAmerican College of Cardiology

Membership: Fellow (1994-present)

Committee Service:

Scientific program selection - abstract reviewer appointments

- ACC 2012
- ACC 2016
- ACC 2018

Guideline reviewer appointments

- 2011 PCI guidelines document
- 2013 ACCF/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease
- 2015 Focused Update on Primary PCI for Patients With STEMI: An Update of the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction and the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
- 2015 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease

Writing Groups

- 2013-2016: Member, writing group to revise ACC/AHA 2012 appropriate use criteria for coronary revascularization in patients with acute coronary syndromes
-
- 2013-2016: Member, writing group to revise ACC/AHA 2012 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease
-
- 2017-2023: Co-Chair, writing group to revise ACC/AHA 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease

Working Groups

- Hypertension working group member since 2021

Leadership roles:

- ACC representative to the National Heart, Lung, and Blood Institute, National Heart Attack Alert Program, 2000-2006

American Heart Association

Membership: Fellow (2001-present)

Committee Service:

- National Faculty, “Get With The Guidelines” program, 2002-2003
- Member, Disease Management Committee, Southeast Affiliate, 2002-2003
- Member, Council on Epidemiology
- Member, Council on Nutrition, Physical Activity and Metabolism
- Member, Council on Quality of Care and Outcomes Research
- QCOR 2016 Planning Committee and Session Moderator
- QCOR 2018 Planning Committee
- 2023 Clinical Cardiology Leadership Committee Member at Large

Reviewer:

- 2011 AHA Policy Statement: The Value of Primordial and Primary Prevention for Cardiovascular Disease
- 2017 AHA Scientific Statement: Medical Nutrition Education, Training and Competencies to Improve Physician-Initiated Diet Counseling for Cardiovascular Disease Prevention

National Lipid Association

Membership: Fellow (2007-present)

American Board of Clinical Lipidology

Leadership role: Board of Directors (2018-2025)

American Society for Preventive Cardiology

Membership: Fellow (2018-present)

Leadership roles:

- 2018 elected to Executive Board of Directors
- 2020 elected Secretary
- 2022 elected Treasurer
- 2024 elected President-Elect

American Diabetes Association

Membership: Middle Tennessee Leadership Council, 2002-2013

PRESENTATIONS

Invited presentations (Grand Rounds, keynote speeches, named lectureships):

- | | |
|------|--|
| 1988 | Stanford University Department of Medicine Grand Rounds (9/22/88)
Stanford, CA |
| 1994 | Vanderbilt University Department of Medicine Grand Rounds, Nashville,
TN |
| 1997 | Saint Thomas Hospital Symposium “Advances in the Treatment of
Hypertension and Hyperlipidemia,” Nashville, TN |

- 1998 Vanderbilt Monthly Primary Care Saturday Seminar, Cholesterol Management: An Even More Aggressive Approach. Nashville, TN
- 1998 Vanderbilt Clinical Pharmacology Grand Rounds: Treatment of Hypertriglyceridemia. Nashville, TN
- 1998 Vanderbilt University, Primary Care Saturday Seminar, Nashville, TN
- 1998 Vanderbilt University, 15th Annual Primary Care Family Medicine Update. Nashville, TN
- 1999 Lecture to 2nd Year Vanderbilt Medical Students, Introduction to Clinical Nutrition, "Nutrition in Prevention and Management of Heart Disease" Nashville, TN
- 2001 Southern Hills Hospital: "Get With the Guidelines," AHA program to bridge the treatment gap. Nashville, TN
- 2004 Dayani Center Conference, Vanderbilt University Medical Center: Traditional vs. Emerging Risk Factors for Cardiovascular Disease. Nashville, TN
- 2004 Nursing Grand Rounds, Vanderbilt University School of Nursing: Update on Screening and Prevention of CHD. Nashville, TN
- 2004 Health Promotion in Practice Conference, Vanderbilt University Medical Center: The American Idle Syndrome. Nashville, TN
- 2005 University of Tennessee Family Practice Grand Rounds: The American Idle Syndrome. Chattanooga, TN
- 2005 Mountain Area Health Education Center: Diabetes 2005: A Clinical Update. Asheville, NC
- 2007 Debate: The COURAGE Trial. Division of Cardiovascular Medicine Grand Rounds. Vanderbilt University, Nashville, TN
- 2007 Vanderbilt Department of Emergency Medicine Grand Rounds 9/18/07. "Evaluation of Chest Pain in the Emergency Room" Nashville, TN
- 2009 Vanderbilt Department of Medicine Grand Rounds 2/19/09: "Treatment of Angina: Interventional Cardiology Confronts the Evidence with COURAGE" Nashville, TN
- 2011 Stanford University Department of Medicine Grand Rounds 6/1/11: To Cath, or Not to Cath? This is the Question (in Stable Coronary Disease Patients). (Presented as a faculty member of Vanderbilt University) Stanford, CA
- 2012 UCLA Cardiology Grand Rounds 2/17/12 Design and Rationale of the ISCHEMIA Trial. Los Angeles, CA
- 2012 Vanderbilt Cardiology Grand Rounds 6/20/12: The ISCHEMIA Trial. Nashville, TN
- 2012 University of Kentucky Cardiology Grand Rounds 12/14/12: ISCHEMIA. Lexington, KY
- 2013 University of Maryland Cardiology Grand Rounds 1/24/13: ISCHEMIA. Baltimore, MD
- 2013 University of Alabama Cardiology Grand Rounds and Medicine Grand Rounds 1/30/13: ISCHEMIA. Birmingham, AL
- 2013 University of South Florida Cardiology Grand Rounds 10/10/13: Management of Stable Ischemic Heart Disease. Tampa, FL
- 2013 Duke University Cardiology Grand Rounds 12/10/13: Management of Stable Ischemic Heart Disease. Durham, NC

- 2014 University of Missouri-Kansas City School of Medicine/Saint Luke's Mid America Heart Institute Cardiology Grand Rounds 1/16/14: Management of Stable Ischemic Heart Disease. Kansas City, MO
- 2014 University of Washington Cardiology Grand Rounds 10/10/14: Management of Stable Ischemic Heart Disease. Seattle, WA
- 2015 NYU Cardiology Grand Rounds 2/20/15: What is an Optimal Lifestyle for Patients with Coronary Disease? New York, NY
- 2015 Weill Cornell Medical College Distinguished Professor Series 5/12/15: To Cath or Not to Cath? Management of Stable Ischemic Heart Disease. New York, NY
- 2015 Stanford Medicine Community Day 5/16/15: Heart Disease Prevention: What you really need to know about diet, exercise, and heart health. Stanford, CA
- 2015 Portland Lipid and Prevention Club 9/15/15: Prevention of MI: Is Optimal Medical Therapy Enough? Portland, OR
- 2015 Oregon Health Sciences University Fellows Conference 9/16/15: Your patient has an abnormal stress test. Now what? Portland, OR
- 2015 UC Irvine Cardiology Grand Rounds 9/17/15: Your patient has an abnormal stress test. Now what? Irvine, CA
- 2016 Stanford Cardiology Grand Rounds 4/28/16: Your patient has an abnormal stress test. Now what? Stanford, CA
- 2016 Stanford Cardiovascular Institute Frontiers in Cardiovascular Science Seminar 6/7/16: Familial Hypercholesterolemia: Clinical, Molecular and Genetic Aspects. (Presented jointly with Josh Knowles, MD, PhD) Stanford, CA
- 2017 Stanford Medicine Grand Rounds 11/15/17: Your patient has an abnormal stress test. Now what? (A debate with William Fearon, MD) Stanford, CA
- 2018 Stanford Medicine Grand Rounds 1/31/18 Coronary Stenting for Stable Angina: Is it a Sham? Stanford, CA
- 2018 Cedars-Sinai Heart Institute. 4/18/18 Benefits of Exercise and Heart Healthy Diet: What is the Evidence? Los Angeles, CA
- 2020 Stanford Health Library Living Better Series. 1/23/20 How to Prevent a Heart Attack in Those with Heart Disease. Stanford, CA
- 2020 Oregon Health Sciences University (Virtual). 4/27/20 ISCHEMIA Findings and Implications
- 2020 Cedars-Sinai Preventive and Consultative Heart Center of Excellence (Virtual). 6/17/20 ISCHEMIA Trial: Implications for Daily Practice
- 2020 Oregon Health Sciences University (Virtual). 6/25/20 Imel-Demots Lectureship. The ISCHEMIA Trial: Implications for Practice
- 2020 Cardiology Grand Rounds, Stony Brook University School of Medicine (Virtual). 10/1/20. Lessons from the ISCHEMIA Trials
- 2020 Stanford Cardiology Grand Rounds (Virtual). 10/15/20. Evaluation and Management of Stable Coronary Disease in the Post-ISCHEMIA Era
- 2021 Preventive Cardiovascular Nurses Association. 4/9/21. Virtual Annual Sessions. Managing Stable Coronary Artery Disease: Invasive vs Conservative Approach.
- 2021 University of Chicago Cardiology Grand Rounds (virtual). 4/23/21. The ISCHEMIA Trial: Implications for Practice.

- 2022 Stanford Medicine Grand Rounds (Virtual, presented jointly with Shoa Clarke, MD, PhD) 1/26/22. Aspirin for the Primary Prevention of Cardiovascular Disease. Stanford, CA
- 2023 Cardiology Grand Rounds Hartford Hospital (Virtual) – 1/9/23. When to Revascularize Patients with Stable Coronary Artery Disease: Lessons from the ISCHEMIA Trial.
- 2025 Medicine Grand Rounds Santa Clara Valley Medical Center (Virtual) – 5/2/25. Primary and Secondary Prevention of Coronary Artery Disease. Santa Clara, CA
- 2025 Stanford Cardiology Grand Rounds 12/18/25. ISCHEMIA Trial: Lessons Learned. Stanford, CA
- 2026 Stanford Cardiology Grand Rounds 4/16/26. 2026 Dyslipidemia Guidelines: What Everyone Should Know. Stanford, CA
- 2026 Stanford Prevention Research Center Grand Rounds 4/16/26. Collateral Damage? Unexplained Cancer Deaths in the Invasive Arm of ISCHEMIA. Stanford, CA
- 2026 Simon Dack Memorial Lecture 4/20/226. Collateral Damage? Unexplained Cancer Deaths in the Invasive Arm of ISCHEMIA. Mount Sinai Hospital, New York, NY.
- 2026 Medicine Grand Rounds Santa Clara Valley Medical Center (Virtual) – 5/18/25. 2026 Lipid Guideline Update. Santa Clara, CA

National and Regional Meetings:

- 1994 Lipid Nurse Task Force First Annual Symposium
- 1995 Georgia Academy of Family Practitioners National Meeting
- 1995 CME meeting prior to American College of Cardiology National Meeting (Sponsor: Emory University) “Non-Lipid Primary and Secondary Prevention Strategies for Coronary Artery Disease”
- 1996 Lipid Nurse Task Force Third Annual Symposium: The Coronary Cocktail: Indications
- 1996 Georgia Academy of Family Practitioners National Meeting
- 1998 American College of Cardiology, Tennessee Chapter
- 1998 Georgia Association of Cardiopulmonary Health, Prevention and Sports Medicine: Beyond LDL: Comprehensive Cardiovascular Disease Risk Reduction
- 1998 Middle Tennessee Association of Diabetes Educators
- 1999 Lecturer, Stanford University, Health Education and Risk Reduction Training Conferences, January, April, July, and October: Current Strategies for Lipid Management (presented as a faculty member at Vanderbilt University) Stanford, CA
- 1999 Moderator of Expert Panel, American College of Physicians-American Society of Internal Medicine Annual Sessions: Evidence Based Primary Prevention of Coronary Artery Disease
- 1999 HDL Symposium: The Imperative to Raise Low Levels of High-Density Lipoprotein Cholesterol
- 2000 Tennessee Association of Cardiovascular and Pulmonary Rehabilitation
- 2000 New Cardiovascular Horizons: Prevention of Coronary Artery Disease: Protective Effect of HDL. New Orleans, LA
- 2001 New Cardiovascular Horizons: NCEP ATP III Guidelines. New Orleans, LA

- 2002 Methodist Healthcare-Memphis Hospitals: NCEP Guidelines. Sea Island, GA
- 2002 Methodist Healthcare-Memphis Hospitals: Diabetes is a Cardiovascular Disease. Sea Island, GA
- 2002 New Cardiovascular Horizons: Diabetes as a Cardiovascular Disease: A Cardiologist's Perspective. New Orleans, LA
- 2002 Preventive Cardiovascular Nurse's Association: Bridging the Treatment Gap
- 2003 University of Tennessee Challenges in Cardiology 2003 Conference: Diabetes is a Cardiovascular Disease. Knoxville, TN
- 2003 Evidence-Based Care Management Conference: Reducing Cardiovascular Risk in the Diabetic Population Chicago, IL; Los Angeles, CA
- 2003 New Cardiovascular Horizons: Benefits of Organizing Large Cardiovascular Groups. New Orleans, LA
- 2004 Diabetes Foundation of Mississippi: Getting to the Heart of Diabetes. Jackson, MS
- 2004 Lipidfacts Center of Excellence Program on Lipid Management: Assessment of CHD Risk: Recommendations for the Use of Conventional and New Risk Markers. Coral Gables, FL
- 2005 Co-moderator of regional symposium on the cardiovascular effects of insulin. Nashville, TN
- 2006 Debate: Does the Metabolic Syndrome Exist? Atlanta, GA; Nashville, TN
- 2006 Debate: How Low Should You Go? (Hemoglobin A1c), Atlanta, GA; Nashville, TN
- 2007 The COURAGE Trial. Atlanta, GA
- 2008 Medical Review for the Primary Care Physician: Choosing the Appropriate Test for Patients with Suspected Coronary Disease; PCI vs. Medical Therapy in Patients with Stable Coronary Disease. Amelia Island, FL
- 2008 Vanderbilt Department of Emergency Medicine: State of the Art Update in Emergency and Acute Care. "Who Gets What Stress Test?" and "Living Longer: Optimal BP, Lipid and Diet" Sandestin, FL
- 2009 Vanderbilt Cardiology 2009 CME Program 2/27/09: "Medical Therapy or Stenting in the Treatment of Angina Pectoris? The COURAGE Trial Revisited" Nashville, TN
- 2009 Gottlieb C. Friesinger Society 4/18/09: The COURAGE Trial: Point/Counterpoint. Chattanooga, TN
- 2011 Vanderbilt Cardiology 2011 CME Program 2/25/11: Stable Ischemic Heart Disease: What is the Best Approach? Nashville, TN
- 2011 Tennessee College of Emergency Physicians Annual Meeting 3/29/11: Chest Pain Risk Stratification
- 2011 8th Annual Ponte Vedra Beach Cardiovascular Symposium 4/30/11: Stable Ischemic Heart Disease: What's Optimal for Evaluation and Treatment? Ponte Vedra Beach, FL
- 2012 Community Health Systems National Meeting of Cardiologists 9/28/12: COURAGE, FAME, and Elective PCI
- 2012 Washington Heart Center Dilemmas in Cardiovascular Disease 10/5/12: To Cath, or Not to Cath? That is the Question. Washington, DC
- 2012 Radiological Society of North America (RSNA) 10/28/12: Refresher Course. Design & Rationale of ISCHEMIA. Chicago, IL

- 2013 Cardiology 2013 (Vanderbilt University Regional Conference) 2/22/13: The Courage to Face ISCHEMIA. Nashville, TN
- 2015 9th Annual Cardiology for the Primary Care Practitioner 10/3/15: Nutritional Supplements in Cardiology. Nashville, TN
- 2016 QCOR 2016: Plenary I: Trials on Trial: What Can Be Done to Sustain and Preserve RCTs in the Future (Session Co-Moderator). Phoenix, AZ
- 2016 QCOR 2016: How to Session for Early Career Attendees and Fellows in Training: How to Interpret Clinical Trials (Session Co-Moderator). Phoenix, AZ
- 2016 QCOR 2016: Prevention Debates: Lipids/HTN/DAPT (Session Co-Moderator). Phoenix, AZ
- 2016 QCOR 2016: Poster Session Moderator. Phoenix, AZ
- 2018 Stanford-Duke Cardiovascular Research Symposium. 11/29/18 Project Baseline: Convergence of Data and Healthcare. Stanford, CA
- 2019 Society for Clinical Trials. 5/21/19 ISCHEMIA Trial Rationale and Design. New Orleans, LA
- 2019 AHA 2019: 11/16/19 ISCHEMIA Trial Results in session entitled State of the Art Cardiovascular Care. Philadelphia, PA
- 2019 16th Global Cardiovascular Clinical Trialists Forum. 12/7/19 ISCHEMIA and COURAGE: Where do we stand for Chronic Coronary Syndromes? Washington, DC
- 2020 American Society for Preventive Cardiology 2020 Congress (Virtual). 7/26/20 ISCHEMIA Trial: Lessons Learned.
- 2020 Society for Cardiovascular CT Prevention Symposium 2020 (Virtual). 8/15/20 Implications of ISCHEMIA for the Preventive Cardiologist
- 2023 37th Annual Conference of the California Society for Cardiac Rehabilitation, 5/12/23 Management of Stable CAD: When to Revascularize. Stanford, CA
- 2023 Top Ten Topic in Clinical Cardiology 2023. 10/6/23 Chronic Coronary Disease Guidelines: What's New Besides the Name? Mount Sinai Hospital. New York, NY
- 2024 UC Davis Health of Women Conference 2024. 5/29/24 Coronary Calcium and Risk Stratification. Napa Valley, CA
- 2024 UC Davis Health of Women Conference 2024. 5/30/24 Defining Optimal Medical Therapy of Ischemic Heart Disease. Napa Valley, CA
- 2024 ACC California Chapter Cardiovascular Team Annual Symposium 2024. 6/1/24 The Multidisciplinary Heart Team. Stanford, CA
- 2024 American Society for Preventive Cardiology Annual Congress. 8/3/24 The Future of CVD Clinical Trials (Panelist). Salt Lake City, UT
- 2025 Right Care Initiative (Virtual). 2/10/25. A Staging System for Coronary Artery Calcification. Berkeley, CA
- 2025 NHLBI Workshop on Emerging Technologies for CAD Imaging: Vision 2040. 9.17.25 Opportunistic Screening.

International Meetings:

- 1997 Moderator, Original Contributions Session, Clinical Application of Hypolipidemic Therapy, American College of Cardiology Scientific Session, Anaheim, CA, USA

- 1998 Co-Chair, Meet the Experts Session, American College of Cardiology Scientific Sessions: Essential Components of Cardiovascular Wellness-Prevention Programs. Atlanta, GA, USA
- 1998 Co-Chair, Meet the Experts Session, American College of Cardiology Scientific Sessions: Primary Prevention of Coronary Disease: Screening and Treating the High Risk Patient. Atlanta, GA, USA
- 2007 The COURAGE Trial. Cayman Islands.
- 2008 The Impact of Age on Outcomes in COURAGE. XXIX Congresso da Sociedade de Cardiologia do Estado de São Paulo. São Paulo, Brazil
- 2008 Impact of PCI on Patients with Severe Angina of Recent Onset in the COURAGE Trial. XXIX Congresso da Sociedade de Cardiologia do Estado de São Paulo. São Paulo, Brazil
- 2009 XII Congresso Sul Brasileiro de Cardiologia. 5/28/09: “Da Experiência do COURAGE a Perspectiva do WISDOM.” Curitiba, Brazil
- 2009 XII Congresso Sul Brasileiro de Cardiologia. 5/29/09: “Evidências em Redução de Placas.” Curitiba, Brazil
- 2009 TCT. Preview of Two Proposed Revascularization vs. Medical Therapy Clinical Trials for Stable Ischemic Heart Disease. San Francisco, CA, USA
- 2010 American College of Cardiology/i2 Joint Session at Annual Scientific Sessions 3/14/10: Stable Coronary Artery Disease: Optimal Medical Therapy and Revascularization Decisions. Atlanta, GA, USA
- 2010 SCAI 5/6/10: Medical Therapy in Current Practice- Who Should You Take Off the Table? San Diego, CA, USA
- 2010 TCT 9/23/10: New Insights into the Predictive Value of Ischemia Before Revascularization. Washington, DC, USA
- 2010 TCT 9/23/10: Core Diabetic Concepts: The Spectrum of Risk Across Diabetics, and Their Evolving Prognosis with Medical Therapy and Revascularization. Washington, DC, USA
- 2010 TCT 9/24/10: Medical Therapy Is Undervalued and Should Be Preferred Unless Significant Ischemia Is Documented. Washington, DC, USA
- 2011 ACC 4/3/11: Annual Scientific Sessions; Clinical Cardiology Spotlight: Symptomatic Cases, Panelist. Orlando, FL, USA
- 2011 TCT 11/8/11: Design, Rationale, and Status of the ISCHEMIA Trial. San Francisco, CA, USA
- 2011 TCT 11/9/11: Discussant in Plenary Session entitled Coronary Revascularization Updates. San Francisco, CA, USA
- 2011 TCT 11/11/11: Discussant in Session entitled Contemporary Management of Stable Coronary Artery Disease. San Francisco, CA, USA
- 2011 TCT 11/11/11: Based on What We Know Today, Medical Therapy is Sufficient for Most Patients with Stable CAD! San Francisco, CA, USA
- 2011 AHA 11/16/11: Plenary Session entitled Challenges in Management of Patients with Stable CAD: Intervening to Improve the Quantity and Quality of Life: Tailoring Medical Therapy, PCI and Surgery to the Right Patient. Orlando, FL, USA
- 2012 ACC 3/26/12: Moderator of Poster Session: Bridging Gaps in Quality. Chicago, IL, USA
- 2012 TCT 10/23/12: When Should Multivessel Disease be Managed Medically? Miami, FL, USA
- 2012 TCT 10/24/12: Design & Rationale of ISCHEMIA. Miami, FL, USA

- 2013 Asociación Nacional de Cardiólogos del Centro Medico La Raza. 8/3/13: How Should We Manage Stable CAD? Leon, Mexico
- 2013 ACC 2013: Limited Culprit Lesion Revascularization is the Preferred Approach for Patients with NSTEMI! (Rapid Fire Clinical Controversies debate) San Francisco, CA, USA
- 2013 ACC 2013: Optimal Medical Therapy after PCI: What is it, is it Achievable and Does it Matter? San Francisco, CA, USA
- 2013 ACC 2013: Non-Culprit Revascularization Should be Symptom-Guided after STEMI (Interventional Controversies in STEMI Management debate) San Francisco, CA, USA
- 2013 TCT 10/28/13: 22nd Annual Nurse and Technologist Symposium: Managing Stable Coronary Artery Disease. Risk/Benefit Favors Medical Therapy First.
- 2013 TCT 10/28/13: Rationale, Design, & Status of the ISCHEMIA Trial. San Francisco, CA, USA
- 2013 TCT 10/29/13: The Decision to Revascularize Must Be Made on the Background of Medical Therapy and Lifestyle Modification. San Francisco, CA
- 2014 ACC 2014 Satellite Symposium: Optimizing PCI Outcomes: A Vision for 2014 (panelist). Washington, DC, USA
- 2014 ACC 2014: Controversies in Interventional Cardiology (Session Co-Chair)
- 2014 European Society of Cardiology 2014: Do We Have Courage to Not Revascularize Stable Ischaemic Heart Disease Patients? Session title: Clinical challenges in ischaemic heart disease - best treatment options with difficult clinical case scenarios. Barcelona, Spain
- 2014 TCT 2014: Where's the Data for Any of This? Medical Therapy First is Most Appropriate! Washington, DC, USA
- 2014 TCT 2014: The Case for Medical Therapy without Revascularization in Most Patients with and without Diabetes. Washington, DC, USA
- 2015 ACC 2015: What is Optimal Medical Therapy for Stable Ischemic Heart Disease? (Session Co-Chair) San Diego, CA, USA
- 2015 ACC 2015: Evidence for Lifestyle Prescription (Session Co-Chair) San Diego, CA, USA
- 2015 SCAI 2015: Beyond Clinical Studies: How to Incorporate Patient's Choice? Session title: Ischemic CAD Best Strategies. (5/8/15) San Diego, CA, USA
- 2015 TCT 2015: Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy! San Francisco, CA, USA
- 2015 TCT 2015: Optimal Medical Therapy After PCI: What Is Optimal, and What Is Realistic? San Francisco, CA, USA
- 2016 ACC 2016: Medical Therapy Alone Should Be Considered Standard of Care! Session title: Current Dilemmas and Controversies: Revascularization Strategies (4/2/16) Chicago, IL, USA
- 2016 ACC 2016: Lipids, Diabetes and ACS (Session Co-Chair) 4/4/16 Chicago, IL, USA
- 2016 ACC 2016: Lipids and Metabolic Syndrome in ACS (ACC Poster Moderator) Chicago, IL, USA

- 2016 TCT 2016: 10/29/16 The Mainstay is Watchful Waiting and Medical Therapy. Washington, DC, USA
- 2016 TCT 2016: 11/1/16 Session Co-Chair: Revascularization Decisions and Therapies for the Diabetic Patient. Washington, DC, USA
- 2016 AHA Scientific Sessions 2016: 11/12/16 The Potential of Machine Learning to Understand Disease: Google's Baseline Study. New Orleans, LA, USA
- 2016 AHA Scientific Sessions 2016: 11/14/16 Moderator of Rapid Fire Oral Abstracts; Session title: Hypertension Clinical II. New Orleans, LA, USA
- 2017 ACC 2017: Putting it All Together: Design and Rationale of the Ongoing ISCHEMIA Trial. Washington DC, USA
- 2017 ACC 2017: Co-Chair of session entitled: Great Debates in Ischemia 2017. Washington DC, USA
- 2017 ACC 2017: Co-Chair of session entitled Beyond the Usual Suspects – Other Dimensions in Prevention. Washington DC, USA
- 2017 TCT 2017: Co-Chair of session entitled Revascularization Decisions and Therapies for the Diabetic Patient. Denver, CO, USA
- 2017 TCT 2017: 10/30/17 Revascularization in Stable Ischemic Heart Disease: What Do the US Guidelines and AUC Say? Denver, CO, USA
- 2017 TCT 2017: 11/1/17 When Is Medical Therapy the Best Choice in the Diabetic Patient? Denver, CO, USA
- 2018 ACC 2018: 3/10/18 What is Refractory Angina, and How Can I Appropriately Manage It? Orlando, FL, USA
- 2018 ACC 2018: 3/12/18 Putting It All Together: Design and Rationale of the Ongoing ISCHEMIA Trial. Orlando, FL, USA
- 2018 TCT 2018: 9/22/18 Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact. San Diego, CA, USA
- 2018 TCT 2018: 9/22/18 Session Moderator: Hot Topic Lunch: The Diabetic Patient Revascularization and Medical Therapies. San Diego, CA, USA
- 2018 TCT 2018: 9/23/18 ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint? San Diego, CA, USA
- 2019 ACC 2019: 3/16/19 Patients with Stable Ischemic Heart Disease Are Best Managed Conservatively Until Truly Refractory Symptoms Develop. New Orleans, LA, USA
- 2020 Cardiovascular Research Technologies. 2/24/20 Findings and Implications of the ISCHEMIA Trial; Quality of Life in the ISCHEMIA Trials. National Harbor, MD, USA
- 2020 ACC 2020 (Virtual conference due to COVID-19 pandemic): 3/29/20 Relationships of Ischemia Severity and Coronary Artery Disease Extent with Clinical Outcomes in the ISCHEMIA Trial. (Featured Clinical Research session.)
- 2020 Society for Cardiovascular CT Annual Meeting (Virtual). 7/17/20 Impact of ISCHEMIA on the Use of Cardiac CT
- 2020 TCT 2020 (Virtual). 10/15/20. Critical Analysis and Clinical Implications from ISCHEMIA in a session entitled Controversies in Stable Chronic Coronary Syndromes: ISCHEMIA and Beyond.
- 2020 AHA 2020 (Virtual). Overview of the ISCHEMIA Trial and Update on Revascularization in Stable Ischemic Heart Disease: Take-aways for Congenital Cardiologists.

- 2021 ACC 2021 (Virtual). ISCHEMIA Trial: Lessons Learned. Session 677: Current Controversies and Debates in CAD Imaging
- 2021 ACC Asia 2021 together with SCS 32nd Annual Scientific Meeting (Virtual). 7/11/21 ISCHEMIA Trial.
- 2021 SCCT Annual Session (Virtual). 7/17/21 ISCHEMIA: The role of cardiac CT.
- 2021 47th Paranaense Congress of Cardiology & International Cardiology Meeting (virtual). 8/5/21 ISCHEMIA is the Final Word!
- 2021 TCT (virtual). 11/4/21 The ISCHEMIA Sub-Studies: Highlights and Take-Home Messages.
- 2021 The fil rouge of atherosclerosis: from brain to heart imaging. (Virtual) 11.5.21 Patient vulnerability, coronary stenosis atherosclerosis: what are the targets and tools? Discussant.
- 2021 The fil rouge of atherosclerosis: from brain to heart imaging. (Virtual) 11.5.21 Results from the trial and evidence from the imaging... is there a fracture? Discussant.
- 2021 ACC Latin America (Virtual). 11/6/21 When to Choose a Conservative Management Strategy.
- 2022 Caribbean Heart Institute (Virtual) 1/27/22 Management of Stable CAD: Lessons from the ISCHEMIA Trial.
- 2023 ACC Scientific Sessions. 3/5/23 Revascularization of Stable Ischemic Heart Disease in the Era of COURAGE, ISCHEMIA, and ORBITA. New Orleans, LA, USA
- 2024 1st Conference on Integrating Early Detection of Heart and Lung Disease through Low-Dose CT. 9/19-9/21/24. Moderator and panelist in several sessions. New York, NY, USA.
- 2024 Rescue Lung Society Conference 10/25-10/26/24. Notification of Coronary Artery Calcium on Lung Screening CT: A New Way to Reduce Risk of Cardiac Events. Also moderator and panelist in several sessions. Boston, MA USA
- 2025 TCT 10.26.25 Stone Cold Facts on Underutilization of Medical Therapy for Chronic Coronary Artery Disease. San Francisco, CA, USA. Also panelist on 10.27.25 for session Personalized Revascularization in the Era of Intravascular Imaging

Visiting Professorships:

- 1995 Visiting Professor, University of Kentucky, Division of Cardiology Grand Rounds, Lexington, KY
- 1996 Visiting Professor, Emory University, Division of Cardiology Grand Rounds and Noon Conference, Atlanta, GA
- 1999 Visiting Professor, University of Kentucky, Division of Cardiology Grand Rounds. Lexington, KY
- 1999 Visiting Professor, University of Alabama (Birmingham), Division of Cardiology Grand Rounds. Birmingham, AL
- 1999 Visiting Professor, Duke University, Cardiology Fellows Rounds. Durham, NC
- 2000 Visiting Professor, Division of Cardiology, Audie Murphy VA, San Antonio, TX
- 2026 Simon Dack, MD, Visiting Professor of Cardiovascular Medicine at Mount Sinai Fuster Heart Hospital

SELECTED INTERVIEWS:

- 1994 Larry King Live Show, January 1994
- 1998 ACCEL: Primary Prevention of Coronary Artery Disease March 31, 1998
- 2007 National Public Radio, Los Angeles, CA regarding the COURAGE trial
- 2015 ACCEL: Management of Stable Ischemic Heart Disease
- 2017 KPCC, NPR Station, Pasadena, CA regarding ORBITA trial
- 2023 ACCEL: Revascularization of Stable Ischemic Heart Disease. 3/5/23
- 2025 ACCEL Lite: The Role of Imaging in Cardiovascular Prevention 9/16/25

SELECTED OTHER MEDIA COVERAGE:

- 2015 New York Times comments on the ISCHEMIA trial June 22, 2015
- 2017 New York Times comments on the FOURIER trial March 17, 2017
- 2017 New York Times comments on the CANTOS trial August 27, 2017
- 2017 New York Times comments on the ORBITA trial November 2, 2017
- 2018 New York Times comments on the cardiac health of President Trump January 17, 2018
- 2018 New York Times comments on polygenic risk score August 13, 2018
- 2019 Interviews about ISCHEMIA:
New York Times
Washington Post
Reuters
Associated Press
Canadian Broadcasting Corporation
- 2020 Washington Post comments on hydroxychloroquine and COVID-19 May 22, 2020
- 2021 KCBS San Francisco interview on USPSTF recommendations on aspirin for primary prevention
- 2024 KABC San Francisco interview on sudden death of Warriors Assistant Coach January 17, 2024
- 2024 New York Times comments on medication adherence March 24, 2024

- 2024 New York Times comments on semaglutide effects on death from COVID August 30, 2024
- 2024 New York Times comments on medical information about Vice President Harris released by the White House October 12, 2024
- 2025 New York Times comments on lepodisiran trial (investigational drug to lower Lp(a)). March 30, 2025
<https://www.nytimes.com/2025/03/30/health/heart-attack-lpa-protein.html>
- 2025 New York Times comments on President Trump's health. September 2, 2025. <https://www.nytimes.com/2025/09/02/us/politics/trump-health-bruise-conspiracies.html>
- 2025 New York Times comments on new Merck oral PCSK9 inhibitor enlicitide. November 8, 2025.
<https://www.nytimes.com/2025/11/08/health/merck-cholesterol-pill-pcsk9.html?smid=nytcore-ios-share&referringSource=articleShare>

COMMUNITY SERVICE

- 2015- Medical Advisory Board, HeartFit for Life (community-based cardiac rehabilitation program, Palo Alto, CA)
- 2019- Stanford Cardiology Free Clinic (Arbor Free Clinic at Samaritan House in Redwood City, CA)
- 2019- Right Care Initiative, Co-chair, Right Care Technical Expert Group

TEACHING

- 1984-1991 Lecturer, Program in Human Biology, Stanford University
- Vanderbilt University School of Medicine:*
- 1993-1999 Attending, Coronary Care Unit and Cardiac Catheterization Laboratory
- 1994, 1995, 1997 Symposium "Beyond Hypercholesterolemia" (Course Director, Lecturer)
- 1994-1999 Division of Cardiovascular Medicine, Clinical Conference, Lecturer and Discussant, 4 hours/yr.
- 1995-1999 Lecturer, Cardiac Rehabilitation lecture series
- 1995-1999 Course Director, Health Promotion clerkship for medical students
- 1996 Lecturer, Pharmacology 325, elective for medical/graduate students
- 1996-1999 Lecturer, Pharmacology 501 (required course)

1996-2000	Lecturer, Ambulatory Care Elective for Vanderbilt medical housestaff
1996-2009	Lecturer, Preventive Medicine (required course)
1999	Lecturer, Nutrition (required course)
1999-2013	Lecturer, Clinical Management Course
2002-2013	Course Director, Health Promotion clerkship for medical students
2004-2013	Lecturer, Nutrition Course (undergraduate course)
2008-2013	Lecturer, Disease, Diagnosis, and Therapeutics (required course, topic: Dyslipidemia)

Stanford University School of Medicine:

2016-2023	Lecturer, Community Health & Prevention Research 260: Preventing Coronary Artery Disease
2016-present	Lecturer, Community Health & Prevention Research 240: Prevention across Medical Disciplines
2016-present	Course Director, Cardiology Grand Rounds
2017	Course Director Community Health & Prevention Research 220: Research in the Community

TRAINEES

(Note: I have not kept a record of trainees/mentees since 1993. This list is reconstructed from memory and may not be complete. At the time of supervision/mentoring, the mentee was at Stanford unless otherwise specified. No end date indicates ongoing mentorship.)

Name	Initial Position	Years	Current Position
<i>Predoctoral Students</i>			
Mark Sanders	Pre-medical student	2019-2020	Medical student Kaiser Perm. SOM
Sujana Balla	Visiting medical student (extern)	2019-	Cardiology fellow Univ. Utah
Neal Chopra	High school student	2022-2024	Accepted to Dartmouth
<i>Nurse Clinicians</i>			
Lisa Ivy	Clinic NP	1997-2004	Arkansas Heart Hospital Clinic NP
Eryn Bryant	Clinic NP	2016-2020	The Ohio State University Wexner Medical Center
Jonathan David	MSN, RN inpatient Cardiac Rehab coordinator	2023-	Same
Molly Lawrence	Clinic RN	2020-2023	Molly Lawrence, RN
<i>Residents</i>			
Ashish Sarraju	Resident	2014-2021	Cardiologist, Cleveland Clinic
Nilay Shah	Resident	2015-2018	Asst. Prof, Northwestern

Viraj Raygor	Resident	2016-2018	Cardiologist, PAMF
Rob Gallo	Resident	2019-2022	Postdoctoral research fellow (VA)
Shyon Parsa	Resident	2024-	Same
Fang Cao	Resident	2024-	Same
<i>Cardiology Fellows</i>			
Don Chomsky	Fellow (Vanderbilt)	1994-1997	Assistant Professor, U. Tennessee Health Science Center
Evans Kemp	Fellow (Vanderbilt)	1994-1997	Cardiologist, Columbus, NC
Laurence Sperling	Fellow (Emory)	1996-1997	Katz Professor in Preventive Cardiology (Emory) and Executive Director, Million Hearts, Division for Heart Disease and Stroke Prevention, CDC.
David Rosenbaum	Fellow (Vanderbilt)	1999-2002	Cardiologist, Colorado Springs
Yasmine Ali	Fellow (Vanderbilt)	2004-2008	Preventive Cardiologist, Nashville
Robert Huang	Fellow (Vanderbilt)	2008-2011	Cardiologist, Chattanooga Heart Institute
Daniel Munoz	Fellow (Vanderbilt)	2012-	Executive Medical Director of the Vanderbilt Heart and Vascular Institute and an Associate Professor of Medicine
Fatima Rodriguez	Fellow	2014-	Associate Professor, Section Chief of Preventive Cardiology (Stanford)
Alex Sandhu	Fellow	2016-	Assistant Professor (Stanford)
Shoa Clarke	Fellow	2017-	Assistant Professor (Stanford)
Lisa Henriksen	Senior Research Scientist	2017-	Associate Professor (NTL-R, Stanford)
Charles German	Fellow (Wake Forest)	2019	Assistant Professor (U. Chicago)
Ramzi Dudum	Fellow	2020-	Assistant Professor (UCSF)
Sneha Jain	Fellow	2021-	Clinical Assistant Professor
Suvasini Lakshmanan	Postdoctoral fellow (Lundquist Institute)	2021-	Cardiology Fellow, U. Iowa
Sofia Gomez	Fellow	2023-	Same
Brian Palmisano	Fellow	2023-	Same
Dan Seung Kim	Fellow	2023-	Same
<i>Faculty</i>			
Sripal Bangalore	Assistant Professor (NYU)	2012-	Professor of Medicine (NYU)
Jonathan Newman	Instructor (NYU)	2013-	Assistant Professor (NYU)
Mandeep Sidhu	Instructor (Albany Medical College)	2013-	Associate Professor and Associate Dean for Clinical Sciences and

			Research Affairs (Albany Medical College)
Jison Hong	Clinical Assistant Professor	2014-2015	Same
Abha Khandelwal	Clinical Assistant Professor	2016-2019	Clinical Associate Professor
Michael Shapiro	Assistant Professor (OHSU)	2016-2019	Fred M. Parrish Professor of Cardiology and Molecular Medicine (Wake Forest University); President-Elect, American Society for Preventive Cardiology
Dan Clark	Clinical Assistant Professor	2023-	Same
Yetsa Tuakli-Worsornu	Associate Professor (University of Pittsburgh)	2023-	Associate Professor (Pending UML appointment, Stanford)